You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameClomipramine
Accession NumberDB01242  (APRD00253, DB07600)
TypeSmall Molecule
GroupsApproved, Vet Approved
DescriptionClomipramine, the 3-chloro analog of imipramine, is a dibenzazepine-derivative tricyclic antidepressant (TCA). TCAs are structurally similar to phenothiazines. They contain a tricyclic ring system with an alkyl amine substituent on the central ring. In non-depressed individuals, clomipramine does not affect mood or arousal, but may cause sedation. In depressed individuals, clomipramine exerts a positive effect on mood. TCAs are potent inhibitors of serotonin and norepinephrine reuptake. Tertiary amine TCAs, such as clomipramine, are more potent inhibitors of serotonin reuptake than secondary amine TCAs, such as nortriptyline and desipramine. TCAs also down-regulate cerebral cortical β-adrenergic receptors and sensitize post-synaptic serotonergic receptors with chronic use. The antidepressant effects of TCAs are thought to be due to an overall increase in serotonergic neurotransmission. TCAs also block histamine-H1 receptors, α1-adrenergic receptors and muscarinic receptors, which accounts for their sedative, hypotensive and anticholinergic effects (e.g. blurred vision, dry mouth, constipation, urinary retention), respectively. See toxicity section below for a complete listing of side effects. Clomipramine may be used to treat obsessive-compulsive disorder and disorders with an obsessive-compulsive component (e.g. depression, schizophrenia, Tourette’s disorder). Unlabeled indications include panic disorder, chronic pain (e.g. central pain, idiopathic pain disorder, tension headache, diabetic peripheral neuropathy, neuropathic pain), cataplexy and associated narcolepsy, autistic disorder, trichotillomania, onchophagia, stuttering, premature ejaculation, and premenstrual syndrome. Clomipramine is rapidly absorbed from the gastrointestinal tract and demethylated in the liver to its primary active metabolite, desmethylclomipramine.
Structure
Thumb
Synonyms
3-(3-chloro-10,11-dihydro-5H-Dibenzo[b,F]azepin-5-yl)-N,N-dimethyl-1-propanamine
3-(3-CHLORO-5H-dibenzo[b,F]azepin-5-yl)-N,N-dimethylpropan-1-amine
3-Chloroimipramine
Chlorimipramine
Clomipramina
Clomipramine
Clomipraminum
g 34586
Monochlorimipramine
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Act Clomipraminetablet10 mgoralActavis Pharma Company2003-02-202016-02-19Canada
Act Clomipraminetablet25 mgoralActavis Pharma Company2003-02-202016-02-19Canada
Act Clomipraminetablet50 mgoralActavis Pharma Company2003-02-202016-02-19Canada
Altius-clomipraminetablet10 mgoralAspri Pharma Canada IncNot applicableNot applicableCanada
Altius-clomipraminetablet25 mgoralAspri Pharma Canada IncNot applicableNot applicableCanada
Altius-clomipraminetablet50 mgoralAspri Pharma Canada IncNot applicableNot applicableCanada
Anafraniltablet10 mgoralAspri Pharma Canada Inc1975-12-31Not applicableCanada
Anafranilcapsule50 mg/1oralMallinckrodt, Inc.2011-03-18Not applicableUs
Anafraniltablet50 mgoralAspri Pharma Canada Inc1981-12-31Not applicableCanada
Anafranilcapsule75 mg/1oralMallinckrodt, Inc.2011-03-18Not applicableUs
Anafraniltablet25 mgoralAspri Pharma Canada Inc1973-12-31Not applicableCanada
Anafranilcapsule25 mg/1oralMallinckrodt, Inc.2011-03-18Not applicableUs
Clomipramine Hydrochloridecapsule25 mg/1oralMallinckrodt, Inc.2015-06-01Not applicableUs
Clomipramine Hydrochloridecapsule50 mg/1oralMallinckrodt, Inc.2015-06-01Not applicableUs
Clomipramine Hydrochloridecapsule75 mg/1oralMallinckrodt, Inc.2015-06-01Not applicableUs
Clomipramine Tablets 10mgtablet10 mgoralPrempharm Inc1997-01-052005-08-05Canada
Clomipramine Tablets 25mgtablet25 mgoralPrempharm Inc1997-01-052005-08-05Canada
Clomipramine Tablets 50mgtablet50 mgoralPrempharm Inc1997-01-052005-08-05Canada
Clomipramine-10 - Tab 10mgtablet10 mgoralPro Doc Limitee1995-12-312010-07-13Canada
Clomipramine-25 - Tab 25mgtablet25 mgoralPro Doc Limitee1995-12-312010-07-13Canada
Clomipramine-50 - Tab 50mgtablet50 mgoralPro Doc Limitee1995-12-312010-07-13Canada
Dom-clomipraminetablet25 mgoralDominion Pharmacal1999-03-10Not applicableCanada
Dom-clomipraminetablet50 mgoralDominion Pharmacal1999-03-10Not applicableCanada
Gen-clomipramine - Tab 10mgtablet10 mgoralGenpharm Ulc1994-12-312009-08-05Canada
Gen-clomipramine - Tab 25mgtablet25 mgoralGenpharm Ulc1994-12-312009-08-05Canada
Gen-clomipramine - Tab 50mgtablet50 mgoralGenpharm Ulc1994-12-312009-08-05Canada
Med Clomipramine Tablets - 25mgtablet25 mgoralMedican Pharma Incorporated1996-08-302011-03-29Canada
Med Clomipramine Tablets - 50mgtablet50 mgoralMedican Pharma Incorporated1996-08-302011-03-29Canada
Novo-clopamine Tab 10mgtablet10 mgoralNovopharm Limited1997-01-062015-10-26Canada
Novo-clopamine Tablets - 25mgtablet25 mgoralNovopharm Limited1995-12-312015-10-26Canada
Novo-clopamine Tablets- 50mgtablet50 mgoralNovopharm Limited1995-12-312015-10-26Canada
Penta-clomipramine - 25mgtablet25 mgoralPentapharm Ltd.1997-06-252004-07-30Canada
Penta-clomipramine - 50mgtablet50 mgoralPentapharm Ltd.1997-06-252004-07-30Canada
PMS-clomipraminetablet25 mgoralPharmascience IncNot applicableNot applicableCanada
PMS-clomipraminetablet50 mgoralPharmascience IncNot applicableNot applicableCanada
PMS-clomipraminetablet10 mgoralPharmascience IncNot applicableNot applicableCanada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-clomipramine Tablets 10mgtablet10 mgoralApotex Inc1993-12-312016-06-30Canada
Apo-clomipramine Tablets 25mgtablet25 mgoralApotex Inc1993-12-312016-06-30Canada
Apo-clomipramine Tablets 50mgtablet50 mgoralApotex Inc1993-12-312016-06-30Canada
Clomipramine Hydrochloridecapsule25 mg/1oralPd Rx Pharmaceuticals, Inc.2009-08-06Not applicableUs
Clomipramine Hydrochloridecapsule25 mg/1oralbryant ranch prepack1996-12-31Not applicableUs
Clomipramine Hydrochloridecapsule25 mg/1oralMylan Pharmaceuticals Inc.1998-05-11Not applicableUs
Clomipramine Hydrochloridecapsule50 mg/1oralPhysicians Total Care, Inc.2005-09-28Not applicableUs
Clomipramine Hydrochloridecapsule50 mg/1oralAmerican Health Packaging2014-08-29Not applicableUs
Clomipramine Hydrochloridecapsule25 mg/1oralSandoz Inc1996-03-29Not applicableUs
Clomipramine Hydrochloridecapsule25 mg/1oralTaro Pharmaceuticals U.S.A., Inc.1996-12-31Not applicableUs
Clomipramine Hydrochloridecapsule50 mg/1oralbryant ranch prepack1996-12-31Not applicableUs
Clomipramine Hydrochloridecapsule50 mg/1oralMylan Pharmaceuticals Inc.1998-05-11Not applicableUs
Clomipramine Hydrochloridecapsule25 mg/1oralGolden State Medical Supply, Inc.1996-12-31Not applicableUs
Clomipramine Hydrochloridecapsule50 mg/1oralSandoz Inc1996-03-29Not applicableUs
Clomipramine Hydrochloridecapsule50 mg/1oralTaro Pharmaceuticals U.S.A., Inc.1996-12-31Not applicableUs
Clomipramine Hydrochloridecapsule25 mg/1oralCarilion Materials Management1996-12-31Not applicableUs
Clomipramine Hydrochloridecapsule75 mg/1oralMylan Pharmaceuticals Inc.1998-05-11Not applicableUs
Clomipramine Hydrochloridecapsule75 mg/1oralGolden State Medical Supply, Inc.1996-12-31Not applicableUs
Clomipramine Hydrochloridecapsule75 mg/1oralSandoz Inc1996-03-29Not applicableUs
Clomipramine Hydrochloridecapsule75 mg/1oralTaro Pharmaceuticals U.S.A., Inc.1996-12-31Not applicableUs
Clomipramine Hydrochloridecapsule25 mg/1oralAmerican Health Packaging2014-08-29Not applicableUs
Clomipramine Hydrochloridecapsule50 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs1996-12-31Not applicableUs
Clomipramine Hydrochloridecapsule50 mg/1oralGolden State Medical Supply, Inc.1996-12-31Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
HydiphenArzneimittelwerk Dresden
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Clomipramine Hydrochloride
17321-77-6
Thumb
  • InChI Key: WIMWMKZEIBHDTH-UHFFFAOYSA-N
  • Monoisotopic Mass: 350.131654192
  • Average Mass: 351.313
DBSALT000028
Categories
UNIINUV44L116D
CAS number303-49-1
WeightAverage: 314.852
Monoisotopic: 314.154976453
Chemical FormulaC19H23ClN2
InChI KeyInChIKey=GDLIGKIOYRNHDA-UHFFFAOYSA-N
InChI
InChI=1S/C19H23ClN2/c1-21(2)12-5-13-22-18-7-4-3-6-15(18)8-9-16-10-11-17(20)14-19(16)22/h3-4,6-7,10-11,14H,5,8-9,12-13H2,1-2H3
IUPAC Name
(3-{14-chloro-2-azatricyclo[9.4.0.0³,⁸]pentadeca-1(11),3,5,7,12,14-hexaen-2-yl}propyl)dimethylamine
SMILES
CN(C)CCCN1C2=CC=CC=C2CCC2=C1C=C(Cl)C=C2
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as dibenzazepines. These are compounds with two benzene rings connected by an azepine ring. Azepine is an unsaturated seven-member heterocycle with one nitrogen atom replacing a carbon atom.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassBenzazepines
Sub ClassDibenzazepines
Direct ParentDibenzazepines
Alternative Parents
Substituents
  • Dibenzazepine
  • Alkyldiarylamine
  • Chlorobenzene
  • Azepine
  • Benzenoid
  • Aryl halide
  • Aryl chloride
  • Tertiary aliphatic amine
  • Tertiary amine
  • Azacycle
  • Hydrocarbon derivative
  • Organonitrogen compound
  • Organochloride
  • Organohalogen compound
  • Amine
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External Descriptors
Pharmacology
IndicationMay be used to treat obsessive-compulsive disorder and disorders with an obsessive-compulsive component (e.g. depression, schizophrenia, Tourette’s disorder). Unlabeled indications include: depression, panic disorder, chronic pain (e.g. central pain, idiopathic pain disorder, tension headache, diabetic peripheral neuropathy, neuropathic pain), cataplexy and associated narcolepsy (limited evidence), autistic disorder (limited evidence), trichotillomania (limited evidence), onchophagia (limited evidence), stuttering (limited evidence), premature ejaculation, and premenstrual syndrome.
PharmacodynamicsClomipramine, a tricyclic antidepressant, is the 3-chloro derivative of Imipramine. It was thought that tricyclic antidepressants work exclusively by inhibiting the re-uptake of the neurotransmitters norepinephrine and serotonin by nerve cells. However, this response occurs immediately, yet mood does not lift for around two weeks. It is now thought that changes occur in receptor sensitivity in the cerebral cortex and hippocampus. The hippocampus is part of the limbic system, a part of the brain involved in emotions. Presynaptic receptors are affected: α1 and β1 receptors are sensitized, α2 receptors are desensitized (leading to increased noradrenaline production). Tricyclics are also known as effective analgesics for different types of pain, especially neuropathic or neuralgic pain.
Mechanism of actionClomipramine is a strong, but not completely selective serotonin reuptake inhibitor (SRI), as the active main metabolite desmethyclomipramine acts preferably as an inhibitor of noradrenaline reuptake. α1-receptor blockage and β-down-regulation have been noted and most likely play a role in the short term effects of clomipramine. A blockade of sodium-channels and NDMA-receptors might, as with other tricyclics, account for its effect in chronic pain, in particular the neuropathic type.
Related Articles
AbsorptionWell absorbed from the GI tract following oral administration. Bioavailability is approximately 50% orally due to extensive first-pass metabolism. Bioavailability is not affected by food. Peak plasma concentrations occurred 2-6 hours following oral administration of a single 50 mg dose. The peak plasma concentration ranged from 56 ng/mL to 154 mg/mL (mean, 92 ng/mL). There are large interindividual variations in plasma concentrations occur, partly due to genetic differences in clomipramine metabolism. On average, steady state plasma concentrations are achieved in 1-2 weeks following multiple dose oral administration. Smoking appears to lower the steady-state plasma concentration of clomipramine, but not its active metabolite desmethylclomipramine.
Volume of distribution

~ 17 L/kg (range: 9-25 L/kg).
Clomipramine is capable of distributing into the cerebrospinal fluid, the brain, and into breast milk.

Protein bindingClomipramine is approximately 97-98% bound to plasma proteins, principally to albumin and possibly to α1-acid glycoprotein. Desmethylclomipramine is 97-99% bound to plasma proteins.
Metabolism

Extensively metabolized in the liver. The main active metabolite is desmethylclomipramine, which is formed by N-demethylation of clomipramine via CYP2C19, 3A4 and 1A2. Other metabolites and their glucuronide conjugates are also produced. Other metabolites of clomipramine include 8-hydroxyclomipramine formed via 8-hydroxylation, 2-hydroxyclomipramine formed via 2-hydroxylation, and clomipramine N-oxide formed by N-oxidation. Desmethylclomipramine is further metabolized to 8-hydroxydesmethylclomipramine and didesmethylclomipramine, which are formed by 8-hydroxylation and N-demethylation, respectively. 8-Hydroxyclomipramine and 8-hydroxydesmethylclomipramine are pharmacologically active; however, their clinical contribution remains unknown.

SubstrateEnzymesProduct
Clomipramine
desmethylclomipramineDetails
Clomipramine
2-hydroxyclomipramineDetails
Clomipramine
8-hydroxyclomipramineDetails
Clomipramine
Not Available
clomipramine N-oxideDetails
desmethylclomipramine
didesmethylclomipramineDetails
2-hydroxyclomipramine
2-hydroxydesmethyl clomipramineDetails
2-hydroxyclomipramine
Not Available
2-hydroxyclomipramine glucuronideDetails
8-hydroxyclomipramine
Not Available
8-hydroxyclomipramine glucuronideDetails
8-hydroxyclomipramine
Not Available
8-hydroxydesmethyl clomipramineDetails
2-hydroxydesmethyl clomipramine
Not Available
2-hydroxydesmethyl clomipramine glucuronideDetails
8-hydroxydesmethyl clomipramine
Not Available
8-hyroxydesmethyl clomipramine glucuronideDetails
Route of eliminationUrine (51-60%) and feces via biliary elimination (24-32%)
Half lifeFollowing oral administration of a single 150 mg dose of clomipramine, the average elimination half-life of clomipramine was 32 hours (range: 19-37 hours) and of desmethylclomipramine was 69 hours (range: 54-77 hours). Elimination half-life may vary substantially with different doses due to saturable kinetics (i.e. metabolism).
ClearanceNot Available
ToxicitySigns and symptoms vary in severity depending upon factors such as the amount of drug absorbed, the age of the patient, and the time elapsed since drug ingestion. Critical manifestations of overdose include cardiac dysrhythmias, severe hypotension, convulsions, and CNS depression including coma. Changes in the electrocardiogram, particularly in QRS axis or width, are clinically significant indicators of tricyclic toxicity. In U.S. clinical trials, 2 deaths occurred in 12 reported cases of acute overdosage with Anafranil either alone or in combination with other drugs. One death involved a patient suspected of ingesting a dose of 7000 mg. The second death involved a patient suspected of ingesting a dose of 5750 mg. Side effects include: sedation, hypotension, blurred vision, dry mouth, constipation, urinary retention, postural hypotension, tachycardia, hypertension, ECG changes, heart failure, impaired memory and delirium, and precipitation of hypomanic or manic episodes in bipolar depression. Withdrawal symptoms include gastrointestinal disturbances, anxiety, and insomnia.
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Clomipramine Metabolism PathwayDrug metabolismSMP00639
SNP Mediated Effects
Interacting Gene/EnzymeSNP RS IDAllele nameDefining changeEffectReference(s)
Cytochrome P450 2D6
Gene symbol: CYP2D6
UniProt: P10635
rs3892097 CYP2D6*4A AllelePoor drug metabolizer, lower dose requirements, higher risk for adverse side effects18070221
SNP Mediated Adverse Drug Reactions
Interacting Gene/EnzymeSNP RS IDAllele nameDefining changeAdverse ReactionReference(s)
Cytochrome P450 2D6
Gene symbol: CYP2D6
UniProt: P10635
rs3892097 CYP2D6*4C > TThose that are homozygous for the poorly metabolizing CYP2D6 alleles are at an increased risk of side effects and decrease drug metabolism18070221
Cytochrome P450 2D6
Gene symbol: CYP2D6
UniProt: P10635
rs3892097 CYP2D6*4C > TThose that are homozygous for the poorly metabolizing CYP2D6 alleles are at an increased risk of side effects and decrease drug metabolism9918137
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9843
Blood Brain Barrier+0.9793
Caco-2 permeable+0.8391
P-glycoprotein substrateSubstrate0.7618
P-glycoprotein inhibitor IInhibitor0.8573
P-glycoprotein inhibitor IIInhibitor0.8387
Renal organic cation transporterInhibitor0.852
CYP450 2C9 substrateNon-substrate0.7875
CYP450 2D6 substrateSubstrate0.8918
CYP450 3A4 substrateSubstrate0.7408
CYP450 1A2 substrateInhibitor0.8374
CYP450 2C9 inhibitorNon-inhibitor0.9176
CYP450 2D6 inhibitorInhibitor0.8932
CYP450 2C19 inhibitorNon-inhibitor0.9025
CYP450 3A4 inhibitorNon-inhibitor0.7971
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.6074
Ames testNon AMES toxic0.8735
CarcinogenicityNon-carcinogens0.8971
BiodegradationNot ready biodegradable0.9967
Rat acute toxicity2.7426 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.889
hERG inhibition (predictor II)Inhibitor0.8029
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
Packagers
Dosage forms
FormRouteStrength
Tabletoral10 mg
Tabletoral25 mg
Tabletoral50 mg
Capsuleoral25 mg/1
Capsuleoral50 mg/1
Capsuleoral75 mg/1
Prices
Unit descriptionCostUnit
Clomipramine hcl powder17.88USD g
Anafranil 25 mg capsule13.51USD capsule
Anafranil 50 mg capsule13.51USD capsule
Anafranil 75 mg capsule13.24USD capsule
ClomiPRAMINE HCl 75 mg capsule1.55USD capsule
Clomipramine 75 mg capsule1.33USD capsule
Clomipramine 50 mg capsule1.01USD capsule
ClomiPRAMINE HCl 25 mg capsule0.88USD capsule
Anafranil 50 mg Tablet0.77USD tablet
Clomipramine 25 mg capsule0.75USD capsule
ClomiPRAMINE HCl 50 mg capsule0.57USD capsule
Apo-Clomipramine 50 mg Tablet0.43USD tablet
Co Clomipramine 50 mg Tablet0.43USD tablet
Anafranil 25 mg Tablet0.42USD tablet
Anafranil 10 mg Tablet0.31USD tablet
Apo-Clomipramine 25 mg Tablet0.23USD tablet
Co Clomipramine 25 mg Tablet0.23USD tablet
Apo-Clomipramine 10 mg Tablet0.17USD tablet
Co Clomipramine 10 mg Tablet0.17USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point191.5-192Schindler, W. and Dietrich, H.; US. Patent 3,515,785; June 2,1970; assigned to Geigy Chemical Corp.
boiling point160-170 °C at 3.00E-01 mm HgPhysProp
water solubility0.294 mg/LNot Available
logP5.19HANSCH,C ET AL. (1995)
Predicted Properties
PropertyValueSource
Water Solubility0.0144 mg/mLALOGPS
logP5.04ALOGPS
logP4.88ChemAxon
logS-4.3ALOGPS
pKa (Strongest Basic)9.2ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area6.48 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity95.41 m3·mol-1ChemAxon
Polarizability35.73 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
MSMass Spectrum (Electron Ionization)splash10-066r-6391000000-e57dc447a97807ce527aView in MoNA
References
Synthesis Reference

Schindler, W. and Dietrich, H.; US. Patent 3,515,785; June 2,1970; assigned to Geigy Chemical Corp.

General ReferencesNot Available
External Links
ATC CodesN06AA04
AHFS Codes
  • 28:16.04.28
PDB EntriesNot Available
FDA labelDownload (712 KB)
MSDSDownload (74.2 KB)
Interactions
Drug Interactions
Drug
1,10-PhenanthrolineThe serum concentration of Clomipramine can be increased when it is combined with 1,10-Phenanthroline.
3,4-DichloroisocoumarinThe serum concentration of Clomipramine can be increased when it is combined with 3,4-Dichloroisocoumarin.
3,4-MethylenedioxyamphetamineClomipramine may increase the stimulatory activities of 3,4-Methylenedioxyamphetamine.
3,4-MethylenedioxymethamphetamineClomipramine may increase the stimulatory activities of 3,4-Methylenedioxymethamphetamine.
4-(2-AMINOETHYL)BENZENESULFONYL FLUORIDEThe serum concentration of Clomipramine can be increased when it is combined with 4-(2-AMINOETHYL)BENZENESULFONYL FLUORIDE.
4-MethoxyamphetamineThe therapeutic efficacy of 4-Methoxyamphetamine can be decreased when used in combination with Clomipramine.
7-NitroindazoleThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Clomipramine.
7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE may increase the serotonergic activities of Clomipramine.
AbirateroneThe serum concentration of Clomipramine can be increased when it is combined with Abiraterone.
AcarboseClomipramine may increase the hypoglycemic activities of Acarbose.
AcebutololThe serum concentration of Acebutolol can be increased when it is combined with Clomipramine.
AcenocoumarolClomipramine may increase the anticoagulant activities of Acenocoumarol.
AcepromazineThe risk or severity of adverse effects can be increased when Acepromazine is combined with Clomipramine.
AceprometazineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Clomipramine.
AcetaminophenThe serum concentration of Acetaminophen can be increased when it is combined with Clomipramine.
AcetophenazineThe risk or severity of adverse effects can be increased when Clomipramine is combined with Acetophenazine.
AcetylcholineThe metabolism of Acetylcholine can be decreased when combined with Clomipramine.
Acetylsalicylic acidClomipramine may increase the antiplatelet activities of Acetylsalicylic acid.
adipiplonThe risk or severity of adverse effects can be increased when adipiplon is combined with Clomipramine.
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Clomipramine.
AgmatineThe therapeutic efficacy of Agmatine can be decreased when used in combination with Clomipramine.
AgomelatineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Clomipramine.
AjmalineThe metabolism of Ajmaline can be decreased when combined with Clomipramine.
AlbiglutideClomipramine may increase the hypoglycemic activities of Albiglutide.
AldosteroneThe serum concentration of Aldosterone can be increased when it is combined with Clomipramine.
AlfaxaloneThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Clomipramine.
AlfentanilAlfentanil may increase the serotonergic activities of Clomipramine.
AlfentanilThe risk or severity of adverse effects can be increased when Clomipramine is combined with Alfentanil.
AlimemazineThe risk or severity of adverse effects can be increased when Alimemazine is combined with Clomipramine.
AlitretinoinThe serum concentration of Alitretinoin can be increased when it is combined with Clomipramine.
AlmotriptanThe metabolism of Almotriptan can be decreased when combined with Clomipramine.
AlmotriptanThe risk or severity of adverse effects can be increased when Almotriptan is combined with Clomipramine.
AlogliptinClomipramine may increase the hypoglycemic activities of Alogliptin.
AlogliptinThe serum concentration of Clomipramine can be increased when it is combined with Alogliptin.
Alpha-1-proteinase inhibitorThe serum concentration of Clomipramine can be increased when it is combined with Alpha-1-proteinase inhibitor.
AlphacetylmethadolAlphacetylmethadol may increase the serotonergic activities of Clomipramine.
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Clomipramine is combined with Alphacetylmethadol.
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Clomipramine.
AlprenololThe serum concentration of Alprenolol can be increased when it is combined with Clomipramine.
AltretamineAltretamine may increase the orthostatic hypotensive activities of Clomipramine.
AmbrisentanThe serum concentration of Ambrisentan can be increased when it is combined with Clomipramine.
AminophenazoneThe metabolism of Aminophenazone can be decreased when combined with Clomipramine.
AmiodaroneThe metabolism of Clomipramine can be decreased when combined with Amiodarone.
AmisulprideThe risk or severity of adverse effects can be increased when Amisulpride is combined with Clomipramine.
AmitriptylineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Clomipramine.
AmitriptylineThe serum concentration of Amitriptyline can be increased when it is combined with Clomipramine.
AmobarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with Clomipramine.
AmoxapineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Clomipramine.
AmperozideThe risk or severity of adverse effects can be increased when Amperozide is combined with Clomipramine.
AmphetamineClomipramine may increase the stimulatory activities of Amphetamine.
AmprenavirThe serum concentration of Clomipramine can be increased when it is combined with Amprenavir.
AmprenavirThe metabolism of Amprenavir can be decreased when combined with Clomipramine.
AmsacrineThe metabolism of Amsacrine can be decreased when combined with Clomipramine.
AnagrelideClomipramine may increase the QTc-prolonging activities of Anagrelide.
AntipyrineThe metabolism of Antipyrine can be decreased when combined with Clomipramine.
Antithrombin III humanThe serum concentration of Clomipramine can be increased when it is combined with Antithrombin III human.
ApixabanThe serum concentration of Clomipramine can be increased when it is combined with Apixaban.
ApomorphineThe therapeutic efficacy of Apomorphine can be decreased when used in combination with Clomipramine.
ApraclonidineThe therapeutic efficacy of Apraclonidine can be decreased when used in combination with Clomipramine.
AprepitantThe serum concentration of Clomipramine can be increased when it is combined with Aprepitant.
AprindineThe metabolism of Aprindine can be decreased when combined with Clomipramine.
AprotininThe serum concentration of Clomipramine can be increased when it is combined with Aprotinin.
ArbutamineThe risk or severity of adverse effects can be increased when Clomipramine is combined with Arbutamine.
ArformoterolThe risk or severity of adverse effects can be increased when Clomipramine is combined with Arformoterol.
ArgatrobanThe serum concentration of Clomipramine can be increased when it is combined with Argatroban.
AripiprazoleThe serum concentration of Aripiprazole can be increased when it is combined with Clomipramine.
AripiprazoleThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Clomipramine.
ArmodafinilThe metabolism of Clomipramine can be decreased when combined with Armodafinil.
ArotinololThe serum concentration of Arotinolol can be increased when it is combined with Clomipramine.
Arsenic trioxideThe serum concentration of Arsenic trioxide can be increased when it is combined with Clomipramine.
ArtemetherThe metabolism of Artemether can be decreased when combined with Clomipramine.
ArticaineThe risk or severity of adverse effects can be increased when Articaine is combined with Clomipramine.
AsenapineThe risk or severity of adverse effects can be increased when Asenapine is combined with Clomipramine.
AstemizoleThe metabolism of Astemizole can be decreased when combined with Clomipramine.
AsunaprevirThe serum concentration of Clomipramine can be increased when it is combined with Asunaprevir.
AtazanavirThe serum concentration of Clomipramine can be increased when it is combined with Atazanavir.
AtenololThe serum concentration of Atenolol can be increased when it is combined with Clomipramine.
AtomoxetineThe metabolism of Clomipramine can be decreased when combined with Atomoxetine.
AxitinibThe serum concentration of Axitinib can be increased when it is combined with Clomipramine.
AzaperoneThe risk or severity of adverse effects can be increased when Azaperone is combined with Clomipramine.
AzelastineClomipramine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Clomipramine.
AzithromycinClomipramine may increase the QTc-prolonging activities of Azithromycin.
AzithromycinThe metabolism of Clomipramine can be decreased when combined with Azithromycin.
BaclofenThe risk or severity of adverse effects can be increased when Baclofen is combined with Clomipramine.
BambuterolThe risk or severity of adverse effects can be increased when Clomipramine is combined with Bambuterol.
BarbitalThe risk or severity of adverse effects can be increased when Barbital is combined with Clomipramine.
BatimastatThe serum concentration of Clomipramine can be increased when it is combined with Batimastat.
BedaquilineClomipramine may increase the QTc-prolonging activities of Bedaquiline.
BefunololThe serum concentration of Befunolol can be increased when it is combined with Clomipramine.
BenazeprilThe serum concentration of Clomipramine can be increased when it is combined with Benazepril.
BendroflumethiazideClomipramine may increase the hyponatremic activities of Bendroflumethiazide.
BenmoxinBenmoxin may increase the serotonergic activities of Clomipramine.
BenzamidineThe serum concentration of Clomipramine can be increased when it is combined with Benzamidine.
BenzatropineThe metabolism of Benzatropine can be decreased when combined with Clomipramine.
BenzocaineThe risk or severity of adverse effects can be increased when Benzocaine is combined with Clomipramine.
BenzphetamineClomipramine may increase the stimulatory activities of Benzphetamine.
Benzyl alcoholThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Clomipramine.
Benzyl alcoholThe metabolism of Benzyl alcohol can be decreased when combined with Clomipramine.
BepridilThe metabolism of Bepridil can be decreased when combined with Clomipramine.
BetamethasoneThe serum concentration of Betamethasone can be increased when it is combined with Clomipramine.
BetaxololThe serum concentration of Betaxolol can be increased when it is combined with Clomipramine.
BetaxololThe metabolism of Clomipramine can be decreased when combined with Betaxolol.
BethanidineThe therapeutic efficacy of Bethanidine can be decreased when used in combination with Clomipramine.
BevantololThe serum concentration of Bevantolol can be increased when it is combined with Clomipramine.
BexaroteneThe serum concentration of Clomipramine can be decreased when it is combined with Bexarotene.
BezitramideBezitramide may increase the serotonergic activities of Clomipramine.
BifeprunoxThe risk or severity of adverse effects can be increased when Clomipramine is combined with Bifeprunox.
BisoprololThe serum concentration of Bisoprolol can be increased when it is combined with Clomipramine.
BivalirudinThe serum concentration of Clomipramine can be increased when it is combined with Bivalirudin.
BoceprevirThe serum concentration of Clomipramine can be increased when it is combined with Boceprevir.
BopindololThe serum concentration of Bopindolol can be increased when it is combined with Clomipramine.
BortezomibThe metabolism of Clomipramine can be decreased when combined with Bortezomib.
BosentanThe serum concentration of Clomipramine can be decreased when it is combined with Bosentan.
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Clomipramine.
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Clomipramine.
BrexpiprazoleThe serum concentration of Brexpiprazole can be increased when it is combined with Clomipramine.
BrexpiprazoleThe risk or severity of adverse effects can be increased when Brexpiprazole is combined with Clomipramine.
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Clomipramine.
BrimonidineThe therapeutic efficacy of Brimonidine can be decreased when used in combination with Clomipramine.
BromazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Clomipramine.
BromocriptineClomipramine may increase the hypoglycemic activities of Bromocriptine.
BromocriptineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Clomipramine.
BrompheniramineThe risk or severity of adverse effects can be increased when Brompheniramine is combined with Clomipramine.
BrompheniramineThe metabolism of Brompheniramine can be decreased when combined with Clomipramine.
BrotizolamThe risk or severity of adverse effects can be increased when Brotizolam is combined with Clomipramine.
BufuralolThe serum concentration of Bufuralol can be increased when it is combined with Clomipramine.
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Clomipramine.
BupivacaineThe metabolism of Bupivacaine can be decreased when combined with Clomipramine.
BupranololThe serum concentration of Bupranolol can be increased when it is combined with Clomipramine.
BuprenorphineBuprenorphine may increase the serotonergic activities of Clomipramine.
BuprenorphineThe metabolism of Buprenorphine can be decreased when combined with Clomipramine.
BupropionThe metabolism of Clomipramine can be decreased when combined with Bupropion.
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Clomipramine.
BuspironeThe metabolism of Buspirone can be decreased when combined with Clomipramine.
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Clomipramine.
ButacaineThe risk or severity of adverse effects can be increased when Butacaine is combined with Clomipramine.
ButalbitalThe risk or severity of adverse effects can be increased when Butalbital is combined with Clomipramine.
ButambenThe risk or severity of adverse effects can be increased when Butamben is combined with Clomipramine.
ButethalThe risk or severity of adverse effects can be increased when Butethal is combined with Clomipramine.
ButorphanolButorphanol may increase the serotonergic activities of Clomipramine.
ButorphanolThe risk or severity of adverse effects can be increased when Clomipramine is combined with Butorphanol.
CabazitaxelThe serum concentration of Cabazitaxel can be increased when it is combined with Clomipramine.
CabergolineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Clomipramine.
CaffeineThe serum concentration of Caffeine can be increased when it is combined with Clomipramine.
CaffeineThe metabolism of Clomipramine can be decreased when combined with Caffeine.
CamptothecinThe serum concentration of Camptothecin can be increased when it is combined with Clomipramine.
CanagliflozinClomipramine may increase the hypoglycemic activities of Canagliflozin.
CandoxatrilThe serum concentration of Clomipramine can be increased when it is combined with Candoxatril.
CaptoprilThe serum concentration of Clomipramine can be increased when it is combined with Captopril.
CaptoprilThe metabolism of Captopril can be decreased when combined with Clomipramine.
CarbamazepineThe metabolism of Clomipramine can be increased when combined with Carbamazepine.
CarbamazepineThe serum concentration of Carbamazepine can be increased when it is combined with Clomipramine.
CarbinoxamineThe risk or severity of adverse effects can be increased when Carbinoxamine is combined with Clomipramine.
CarfentanilCarfentanil may increase the serotonergic activities of Clomipramine.
CarfentanilThe risk or severity of adverse effects can be increased when Clomipramine is combined with Carfentanil.
CarfilzomibThe serum concentration of Carfilzomib can be increased when it is combined with Clomipramine.
CariprazineThe risk or severity of adverse effects can be increased when Clomipramine is combined with Cariprazine.
CarisoprodolThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Clomipramine.
CaroxazoneCaroxazone may increase the serotonergic activities of Clomipramine.
CarteololThe serum concentration of Carteolol can be increased when it is combined with Clomipramine.
CarvedilolThe serum concentration of Carvedilol can be increased when it is combined with Clomipramine.
CelecoxibThe metabolism of Clomipramine can be decreased when combined with Celecoxib.
CeliprololThe serum concentration of Celiprolol can be increased when it is combined with Clomipramine.
CephalexinThe metabolism of Cephalexin can be decreased when combined with Clomipramine.
CeritinibThe serum concentration of Clomipramine can be increased when it is combined with Ceritinib.
CeritinibClomipramine may increase the QTc-prolonging activities of Ceritinib.
CerivastatinThe serum concentration of Cerivastatin can be increased when it is combined with Clomipramine.
CetirizineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Clomipramine.
CevimelineThe metabolism of Cevimeline can be decreased when combined with Clomipramine.
Chloral hydrateThe risk or severity of adverse effects can be increased when Chloral hydrate is combined with Clomipramine.
ChloramphenicolThe metabolism of Clomipramine can be decreased when combined with Chloramphenicol.
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Clomipramine.
ChlordiazepoxideThe metabolism of Chlordiazepoxide can be decreased when combined with Clomipramine.
ChlormezanoneThe risk or severity of adverse effects can be increased when Chlormezanone is combined with Clomipramine.
ChloroprocaineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Clomipramine.
ChloroquineClomipramine may increase the QTc-prolonging activities of Chloroquine.
ChloroquineThe metabolism of Clomipramine can be decreased when combined with Chloroquine.
ChlorothiazideClomipramine may increase the hyponatremic activities of Chlorothiazide.
ChlorphenamineThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Clomipramine.
ChlorphenamineThe metabolism of Chlorphenamine can be decreased when combined with Clomipramine.
ChlorphentermineClomipramine may increase the stimulatory activities of Chlorphentermine.
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Clomipramine.
ChlorpropamideClomipramine may increase the hypoglycemic activities of Chlorpropamide.
ChlorprothixeneThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Clomipramine.
ChlorthalidoneClomipramine may increase the hyponatremic activities of Chlorthalidone.
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Clomipramine.
ChlorzoxazoneThe metabolism of Chlorzoxazone can be decreased when combined with Clomipramine.
CholecalciferolThe metabolism of Clomipramine can be decreased when combined with Cholecalciferol.
ChymostatinThe serum concentration of Clomipramine can be increased when it is combined with Chymostatin.
CilastatinThe serum concentration of Clomipramine can be increased when it is combined with Cilastatin.
CilazaprilThe serum concentration of Clomipramine can be increased when it is combined with Cilazapril.
CilostazolThe metabolism of Cilostazol can be decreased when combined with Clomipramine.
CimetidineThe metabolism of Clomipramine can be decreased when combined with Cimetidine.
CimetidineThe serum concentration of Cimetidine can be increased when it is combined with Clomipramine.
CinacalcetThe serum concentration of Clomipramine can be increased when it is combined with Cinacalcet.
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Clomipramine.
CinnarizineThe metabolism of Cinnarizine can be decreased when combined with Clomipramine.
CiprofloxacinClomipramine may increase the QTc-prolonging activities of Ciprofloxacin.
CirazolineClomipramine may increase the vasopressor activities of Cirazoline.
CisaprideClomipramine may increase the QTc-prolonging activities of Cisapride.
CisplatinThe serum concentration of Cisplatin can be increased when it is combined with Clomipramine.
CitalopramThe risk or severity of adverse effects can be increased when Clomipramine is combined with Citalopram.
CitalopramThe metabolism of Clomipramine can be decreased when combined with Citalopram.
ClarithromycinClomipramine may increase the QTc-prolonging activities of Clarithromycin.
ClarithromycinThe metabolism of Clomipramine can be decreased when combined with Clarithromycin.
ClemastineThe risk or severity of adverse effects can be increased when Clemastine is combined with Clomipramine.
ClenbuterolThe risk or severity of adverse effects can be increased when Clomipramine is combined with Clenbuterol.
ClevidipineThe metabolism of Clevidipine can be decreased when combined with Clomipramine.
ClidiniumThe risk or severity of adverse effects can be increased when Clidinium is combined with Clomipramine.
ClobazamThe risk or severity of adverse effects can be increased when Clobazam is combined with Clomipramine.
ClobazamThe serum concentration of Clobazam can be increased when it is combined with Clomipramine.
clomethiazoleThe risk or severity of adverse effects can be increased when clomethiazole is combined with Clomipramine.
ClomifeneThe serum concentration of Clomifene can be increased when it is combined with Clomipramine.
ClonazepamThe risk or severity of adverse effects can be increased when Clonazepam is combined with Clomipramine.
ClonidineThe risk or severity of adverse effects can be increased when Clonidine is combined with Clomipramine.
ClonidineThe therapeutic efficacy of Clonidine can be decreased when used in combination with Clomipramine.
ClopidogrelThe serum concentration of Clopidogrel can be increased when it is combined with Clomipramine.
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Clomipramine.
ClotrimazoleThe metabolism of Clomipramine can be decreased when combined with Clotrimazole.
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Clomipramine.
CobicistatThe serum concentration of Clomipramine can be increased when it is combined with Cobicistat.
CobimetinibThe serum concentration of Cobimetinib can be increased when it is combined with Clomipramine.
CocaineThe risk or severity of adverse effects can be increased when Cocaine is combined with Clomipramine.
CodeineThe therapeutic efficacy of Codeine can be decreased when used in combination with Clomipramine.
CodeineCodeine may increase the serotonergic activities of Clomipramine.
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Clomipramine.
ConivaptanThe serum concentration of Clomipramine can be increased when it is combined with Conivaptan.
Conjugated Equine EstrogensThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Clomipramine.
CrizotinibClomipramine may increase the QTc-prolonging activities of Crizotinib.
CrizotinibThe metabolism of Clomipramine can be decreased when combined with Crizotinib.
CyamemazineThe risk or severity of adverse effects can be increased when Clomipramine is combined with Cyamemazine.
CyclizineThe risk or severity of adverse effects can be increased when Cyclizine is combined with Clomipramine.
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Clomipramine.
CyclobenzaprineThe metabolism of Cyclobenzaprine can be decreased when combined with Clomipramine.
CyclophosphamideThe metabolism of Cyclophosphamide can be decreased when combined with Clomipramine.
CyclosporineThe metabolism of Clomipramine can be decreased when combined with Cyclosporine.
CyclosporineThe serum concentration of Cyclosporine can be increased when it is combined with Clomipramine.
CyproheptadineThe therapeutic efficacy of Clomipramine can be decreased when used in combination with Cyproheptadine.
CyproheptadineThe risk or severity of adverse effects can be increased when Clomipramine is combined with Cyproheptadine.
Cyproterone acetateThe serum concentration of Clomipramine can be decreased when it is combined with Cyproterone acetate.
Dabigatran etexilateThe serum concentration of Clomipramine can be increased when it is combined with Dabigatran etexilate.
DabrafenibThe serum concentration of Clomipramine can be decreased when it is combined with Dabrafenib.
DabrafenibThe serum concentration of Dabrafenib can be increased when it is combined with Clomipramine.
DactinomycinThe serum concentration of Dactinomycin can be increased when it is combined with Clomipramine.
DantroleneThe risk or severity of adverse effects can be increased when Dantrolene is combined with Clomipramine.
DapagliflozinClomipramine may increase the hypoglycemic activities of Dapagliflozin.
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Clomipramine.
DapoxetineThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Clomipramine.
DarifenacinThe metabolism of Clomipramine can be decreased when combined with Darifenacin.
DarunavirThe serum concentration of Clomipramine can be increased when it is combined with Darunavir.
DasabuvirThe metabolism of Dasabuvir can be decreased when combined with Clomipramine.
DasatinibThe serum concentration of Clomipramine can be increased when it is combined with Dasatinib.
DaunorubicinThe serum concentration of Daunorubicin can be increased when it is combined with Clomipramine.
DebrisoquinThe serum concentration of Debrisoquin can be increased when it is combined with Clomipramine.
DeferasiroxThe serum concentration of Clomipramine can be decreased when it is combined with Deferasirox.
DelavirdineThe metabolism of Clomipramine can be decreased when combined with Delavirdine.
deramciclaneThe risk or severity of adverse effects can be increased when deramciclane is combined with Clomipramine.
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Clomipramine.
DesipramineThe risk or severity of adverse effects can be increased when Desipramine is combined with Clomipramine.
DesipramineThe metabolism of Desipramine can be decreased when combined with Clomipramine.
DesloratadineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Clomipramine.
DesmopressinThe risk or severity of adverse effects can be increased when Clomipramine is combined with Desmopressin.
DesvenlafaxineThe risk or severity of adverse effects can be increased when Clomipramine is combined with Desvenlafaxine.
DetomidineThe risk or severity of adverse effects can be increased when Detomidine is combined with Clomipramine.
DexamethasoneThe serum concentration of Clomipramine can be decreased when it is combined with Dexamethasone.
DexamethasoneThe serum concentration of Dexamethasone can be increased when it is combined with Clomipramine.
DexbrompheniramineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Clomipramine.
DexfenfluramineThe metabolism of Dexfenfluramine can be decreased when combined with Clomipramine.
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Clomipramine.
DexmedetomidineThe therapeutic efficacy of Dexmedetomidine can be decreased when used in combination with Clomipramine.
DexmethylphenidateThe risk or severity of adverse effects can be increased when Dexmethylphenidate is combined with Clomipramine.
DexmethylphenidateThe metabolism of Dexmethylphenidate can be decreased when combined with Clomipramine.
DextroamphetamineClomipramine may increase the stimulatory activities of Dextroamphetamine.
DextromethorphanThe metabolism of Dextromethorphan can be decreased when combined with Clomipramine.
DextromethorphanThe risk or severity of adverse effects can be increased when Dextromethorphan is combined with Clomipramine.
DextromoramideDextromoramide may increase the serotonergic activities of Clomipramine.
DextromoramideThe risk or severity of adverse effects can be increased when Clomipramine is combined with Dextromoramide.
DextropropoxypheneDextropropoxyphene may increase the serotonergic activities of Clomipramine.
DextropropoxypheneThe risk or severity of adverse effects can be increased when Clomipramine is combined with Dextropropoxyphene.
DezocineDezocine may increase the serotonergic activities of Clomipramine.
DezocineThe risk or severity of adverse effects can be increased when Clomipramine is combined with Dezocine.
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Clomipramine.
DiazepamThe serum concentration of Diazepam can be increased when it is combined with Clomipramine.
DicoumarolClomipramine may increase the anticoagulant activities of Dicoumarol.
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be increased when it is combined with Clomipramine.
DifenoxinThe risk or severity of adverse effects can be increased when Difenoxin is combined with Clomipramine.
DigitoxinThe serum concentration of Digitoxin can be increased when it is combined with Clomipramine.
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Clomipramine.
DihydrocodeineDihydrocodeine may increase the serotonergic activities of Clomipramine.
DihydrocodeineThe metabolism of Dihydrocodeine can be decreased when combined with Clomipramine.
DihydroergotamineThe therapeutic efficacy of Dihydroergotamine can be decreased when used in combination with Clomipramine.
DihydroergotamineThe metabolism of Clomipramine can be decreased when combined with Dihydroergotamine.
DihydroetorphineDihydroetorphine may increase the serotonergic activities of Clomipramine.
DihydroetorphineThe risk or severity of adverse effects can be increased when Clomipramine is combined with Dihydroetorphine.
DihydromorphineDihydromorphine may increase the serotonergic activities of Clomipramine.
DihydromorphineThe risk or severity of adverse effects can be increased when Clomipramine is combined with Dihydromorphine.
DihydrotestosteroneThe serum concentration of Dihydrotestosterone can be increased when it is combined with Clomipramine.
DiltiazemThe metabolism of Clomipramine can be decreased when combined with Diltiazem.
DiltiazemThe serum concentration of Diltiazem can be increased when it is combined with Clomipramine.
DimenhydrinateThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Clomipramine.
DiphenhydramineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Clomipramine.
DiphenhydramineThe metabolism of Diphenhydramine can be decreased when combined with Clomipramine.
DiphenoxylateDiphenoxylate may increase the serotonergic activities of Clomipramine.
DiphenoxylateThe risk or severity of adverse effects can be increased when Clomipramine is combined with Diphenoxylate.
DipivefrinThe therapeutic efficacy of Dipivefrin can be decreased when used in combination with Clomipramine.
DipyridamoleThe serum concentration of Dipyridamole can be increased when it is combined with Clomipramine.
DisopyramideClomipramine may increase the hypoglycemic activities of Disopyramide.
DobutamineThe risk or severity of adverse effects can be increased when Clomipramine is combined with Dobutamine.
DocetaxelThe serum concentration of Docetaxel can be increased when it is combined with Clomipramine.
DofetilideClomipramine may increase the QTc-prolonging activities of Dofetilide.
DolasetronClomipramine may increase the QTc-prolonging activities of Dolasetron.
DolasetronDolasetron may increase the serotonergic activities of Clomipramine.
DomperidoneThe serum concentration of Domperidone can be increased when it is combined with Clomipramine.
DonepezilThe metabolism of Donepezil can be decreased when combined with Clomipramine.
DopamineThe metabolism of Dopamine can be decreased when combined with Clomipramine.
DoramectinThe risk or severity of adverse effects can be increased when Doramectin is combined with Clomipramine.
DosulepinThe serum concentration of Dosulepin can be increased when it is combined with Clomipramine.
DoxazosinThe metabolism of Doxazosin can be decreased when combined with Clomipramine.
DoxepinThe risk or severity of adverse effects can be increased when Doxepin is combined with Clomipramine.
DoxepinThe metabolism of Doxepin can be decreased when combined with Clomipramine.
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Clomipramine.
DoxycyclineThe metabolism of Clomipramine can be decreased when combined with Doxycycline.
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Clomipramine.
DoxylamineThe risk or severity of adverse effects can be increased when Clomipramine is combined with Doxylamine.
DPDPEDPDPE may increase the serotonergic activities of Clomipramine.
DPDPEThe risk or severity of adverse effects can be increased when Clomipramine is combined with DPDPE.
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Clomipramine.
DronedaroneThe metabolism of Clomipramine can be decreased when combined with Dronedarone.
DroperidolThe risk or severity of adverse effects can be increased when Droperidol is combined with Clomipramine.
DrotebanolThe risk or severity of adverse effects can be increased when Drotebanol is combined with Clomipramine.
DroxidopaThe therapeutic efficacy of Droxidopa can be decreased when used in combination with Clomipramine.
DulaglutideClomipramine may increase the hypoglycemic activities of Dulaglutide.
DuloxetineThe metabolism of Clomipramine can be decreased when combined with Duloxetine.
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Clomipramine.
EcabetThe serum concentration of Clomipramine can be increased when it is combined with Ecabet.
EcgonineThe risk or severity of adverse effects can be increased when Ecgonine is combined with Clomipramine.
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when ECGONINE METHYL ESTER is combined with Clomipramine.
EdoxabanThe serum concentration of Clomipramine can be increased when it is combined with Edoxaban.
EfavirenzThe risk or severity of adverse effects can be increased when Efavirenz is combined with Clomipramine.
ElafinThe serum concentration of Clomipramine can be increased when it is combined with Elafin.
EletriptanThe serum concentration of Eletriptan can be increased when it is combined with Clomipramine.
EletriptanThe risk or severity of adverse effects can be increased when Eletriptan is combined with Clomipramine.
EliglustatThe metabolism of Eliglustat can be decreased when combined with Clomipramine.
EmpagliflozinClomipramine may increase the hypoglycemic activities of Empagliflozin.
EnalaprilThe serum concentration of Clomipramine can be increased when it is combined with Enalapril.
EnalaprilatThe serum concentration of Clomipramine can be increased when it is combined with Enalaprilat.
EnalkirenThe serum concentration of Clomipramine can be increased when it is combined with Enalkiren.
EncainideThe metabolism of Encainide can be decreased when combined with Clomipramine.
EnclomipheneThe metabolism of Enclomiphene can be decreased when combined with Clomipramine.
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Clomipramine.
EntacaponeThe risk or severity of adverse effects can be increased when Entacapone is combined with Clomipramine.
EnzalutamideThe serum concentration of Clomipramine can be decreased when it is combined with Enzalutamide.
EphedraThe therapeutic efficacy of Ephedra can be decreased when used in combination with Clomipramine.
EpinastineThe serum concentration of Epinastine can be increased when it is combined with Clomipramine.
EpinephrineThe therapeutic efficacy of Epinephrine can be decreased when used in combination with Clomipramine.
Ergoloid mesylateThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Clomipramine.
ErgonovineThe risk or severity of adverse effects can be increased when Clomipramine is combined with Ergonovine.
ErgotamineClomipramine may increase the vasopressor activities of Ergotamine.
ErgotamineThe risk or severity of adverse effects can be increased when Ergotamine is combined with Clomipramine.
ErlotinibThe serum concentration of Erlotinib can be increased when it is combined with Clomipramine.
ErythromycinClomipramine may increase the QTc-prolonging activities of Erythromycin.
ErythromycinThe metabolism of Clomipramine can be decreased when combined with Erythromycin.
EscitalopramThe risk or severity of adverse effects can be increased when Clomipramine is combined with Escitalopram.
EscitalopramEscitalopram may increase the serotonergic activities of Clomipramine.
Eslicarbazepine acetateThe serum concentration of Clomipramine can be decreased when it is combined with Eslicarbazepine acetate.
EsmirtazapineThe metabolism of Esmirtazapine can be decreased when combined with Clomipramine.
EsmololThe serum concentration of Esmolol can be increased when it is combined with Clomipramine.
EsomeprazoleThe metabolism of Clomipramine can be decreased when combined with Esomeprazole.
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Clomipramine.
EstradiolThe serum concentration of Estradiol can be increased when it is combined with Clomipramine.
EstriolThe serum concentration of Estriol can be increased when it is combined with Clomipramine.
EstroneThe serum concentration of Estrone can be increased when it is combined with Clomipramine.
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Clomipramine.
EthanolClomipramine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.
EthanolThe risk or severity of adverse effects can be increased when Ethanol is combined with Clomipramine.
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Clomipramine.
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Clomipramine.
EthosuximideThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Clomipramine.
EthotoinThe risk or severity of adverse effects can be increased when Ethotoin is combined with Clomipramine.
Ethyl biscoumacetateClomipramine may increase the anticoagulant activities of Ethyl biscoumacetate.
Ethyl carbamateThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Clomipramine.
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Clomipramine.
EthylmorphineEthylmorphine may increase the serotonergic activities of Clomipramine.
EthylmorphineThe metabolism of Ethylmorphine can be decreased when combined with Clomipramine.
EtidocaineThe risk or severity of adverse effects can be increased when Etidocaine is combined with Clomipramine.
EtifoxineThe risk or severity of adverse effects can be increased when Etifoxine is combined with Clomipramine.
EtizolamThe risk or severity of adverse effects can be increased when Etizolam is combined with Clomipramine.
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Clomipramine.
EtomidateThe therapeutic efficacy of Etomidate can be decreased when used in combination with Clomipramine.
EtoperidoneThe risk or severity of adverse effects can be increased when Clomipramine is combined with Etoperidone.
EtoperidoneEtoperidone may increase the serotonergic activities of Clomipramine.
EtoposideThe serum concentration of Etoposide can be increased when it is combined with Clomipramine.
EtoricoxibThe metabolism of Etoricoxib can be decreased when combined with Clomipramine.
EtorphineEtorphine may increase the serotonergic activities of Clomipramine.
EtorphineThe risk or severity of adverse effects can be increased when Clomipramine is combined with Etorphine.
EtravirineThe serum concentration of Clomipramine can be decreased when it is combined with Etravirine.
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Clomipramine.
ExenatideClomipramine may increase the hypoglycemic activities of Exenatide.
EzetimibeThe serum concentration of Ezetimibe can be increased when it is combined with Clomipramine.
EzogabineThe risk or severity of adverse effects can be increased when Ezogabine is combined with Clomipramine.
FelbamateThe risk or severity of adverse effects can be increased when Felbamate is combined with Clomipramine.
FencamfamineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Clomipramine.
FenfluramineThe risk or severity of adverse effects can be increased when Clomipramine is combined with Fenfluramine.
FenfluramineFenfluramine may increase the serotonergic activities of Clomipramine.
FenoterolThe risk or severity of adverse effects can be increased when Clomipramine is combined with Fenoterol.
FentanylFentanyl may increase the serotonergic activities of Clomipramine.
FentanylThe risk or severity of adverse effects can be increased when Clomipramine is combined with Fentanyl.
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Clomipramine.
FexofenadineThe risk or severity of adverse effects can be increased when Fexofenadine is combined with Clomipramine.
FexofenadineThe serum concentration of Fexofenadine can be increased when it is combined with Clomipramine.
FidaxomicinThe serum concentration of Fidaxomicin can be increased when it is combined with Clomipramine.
FingolimodThe metabolism of Fingolimod can be decreased when combined with Clomipramine.
FlecainideClomipramine may increase the QTc-prolonging activities of Flecainide.
FlibanserinThe risk or severity of adverse effects can be increased when Flibanserin is combined with Clomipramine.
FluconazoleThe metabolism of Clomipramine can be decreased when combined with Fluconazole.
FludiazepamThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Clomipramine.
FlunarizineThe risk or severity of adverse effects can be increased when Flunarizine is combined with Clomipramine.
FlunarizineThe metabolism of Flunarizine can be decreased when combined with Clomipramine.
FlunitrazepamThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Clomipramine.
FluoxetineThe risk or severity of adverse effects can be increased when Clomipramine is combined with Fluoxetine.
FluoxetineThe metabolism of Clomipramine can be decreased when combined with Fluoxetine.
FlupentixolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Clomipramine.
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Clomipramine.
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Clomipramine.
FluspirileneThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Clomipramine.
Fluticasone furoateThe serum concentration of Fluticasone furoate can be increased when it is combined with Clomipramine.
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Fluticasone Propionate is combined with Clomipramine.
FluvastatinThe metabolism of Fluvastatin can be decreased when combined with Clomipramine.
FluvoxamineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Clomipramine.
FormoterolThe risk or severity of adverse effects can be increased when Clomipramine is combined with Formoterol.
FosamprenavirThe serum concentration of Clomipramine can be increased when it is combined with Fosamprenavir.
FosaprepitantThe serum concentration of Clomipramine can be increased when it is combined with Fosaprepitant.
FosinoprilThe serum concentration of Clomipramine can be increased when it is combined with Fosinopril.
FosphenytoinThe risk or severity of adverse effects can be increased when Fosphenytoin is combined with Clomipramine.
FospropofolThe risk or severity of adverse effects can be increased when Fospropofol is combined with Clomipramine.
FrovatriptanThe risk or severity of adverse effects can be increased when Frovatriptan is combined with Clomipramine.
FurazolidoneFurazolidone may increase the serotonergic activities of Clomipramine.
Fusidic AcidThe serum concentration of Clomipramine can be increased when it is combined with Fusidic Acid.
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Clomipramine.
gabapentin enacarbilThe risk or severity of adverse effects can be increased when gabapentin enacarbil is combined with Clomipramine.
Gadobenic acidClomipramine may increase the QTc-prolonging activities of Gadobenic acid.
GalantamineThe metabolism of Galantamine can be decreased when combined with Clomipramine.
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Clomipramine.
GefitinibThe serum concentration of Gefitinib can be increased when it is combined with Clomipramine.
GeldanamycinThe serum concentration of Clomipramine can be increased when it is combined with Geldanamycin.
GemcitabineThe serum concentration of Gemcitabine can be increased when it is combined with Clomipramine.
GemfibrozilThe metabolism of Clomipramine can be decreased when combined with Gemfibrozil.
GemifloxacinClomipramine may increase the QTc-prolonging activities of Gemifloxacin.
GliclazideClomipramine may increase the hypoglycemic activities of Gliclazide.
GlimepirideClomipramine may increase the hypoglycemic activities of Glimepiride.
GlipizideClomipramine may increase the hypoglycemic activities of Glipizide.
GlutethimideThe risk or severity of adverse effects can be increased when Glutethimide is combined with Clomipramine.
GlyburideClomipramine may increase the hypoglycemic activities of Glyburide.
GM6001The serum concentration of Clomipramine can be increased when it is combined with GM6001.
GoserelinClomipramine may increase the QTc-prolonging activities of Goserelin.
GranisetronClomipramine may increase the QTc-prolonging activities of Granisetron.
GranisetronGranisetron may increase the serotonergic activities of Clomipramine.
GrazoprevirThe serum concentration of Grazoprevir can be increased when it is combined with Clomipramine.
GrepafloxacinThe serum concentration of Grepafloxacin can be increased when it is combined with Clomipramine.
GuanabenzThe therapeutic efficacy of Guanabenz can be decreased when used in combination with Clomipramine.
GuanfacineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Clomipramine.
GuanfacineThe therapeutic efficacy of Guanfacine can be decreased when used in combination with Clomipramine.
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Clomipramine.
HalofantrineThe metabolism of Halofantrine can be decreased when combined with Clomipramine.
HaloperidolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Clomipramine.
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Clomipramine.
HalothaneThe metabolism of Halothane can be decreased when combined with Clomipramine.
HeroinHeroin may increase the serotonergic activities of Clomipramine.
HeroinThe risk or severity of adverse effects can be increased when Clomipramine is combined with Heroin.
HexobarbitalThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Clomipramine.
HirulogThe serum concentration of Clomipramine can be increased when it is combined with Hirulog.
HydracarbazineHydracarbazine may increase the serotonergic activities of Clomipramine.
HydrochlorothiazideClomipramine may increase the hyponatremic activities of Hydrochlorothiazide.
HydrocodoneHydrocodone may increase the serotonergic activities of Clomipramine.
HydrocodoneThe metabolism of Hydrocodone can be decreased when combined with Clomipramine.
HydrocortisoneThe serum concentration of Hydrocortisone can be increased when it is combined with Clomipramine.
HydroflumethiazideClomipramine may increase the hyponatremic activities of Hydroflumethiazide.
HydromorphoneHydromorphone may increase the serotonergic activities of Clomipramine.
HydromorphoneThe metabolism of Hydromorphone can be decreased when combined with Clomipramine.
Hydroxyamphetamine hydrobromideClomipramine may increase the stimulatory activities of Hydroxyamphetamine hydrobromide.
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Clomipramine.
HydroxyzineThe risk or severity of adverse effects can be increased when Clomipramine is combined with Hydroxyzine.
IbrutinibThe metabolism of Ibrutinib can be decreased when combined with Clomipramine.
IbuprofenThe serum concentration of Ibuprofen can be increased when it is combined with Clomipramine.
IbutilideClomipramine may increase the QTc-prolonging activities of Ibutilide.
IdarubicinThe metabolism of Idarubicin can be decreased when combined with Clomipramine.
IdelalisibThe serum concentration of Clomipramine can be increased when it is combined with Idelalisib.
IloperidoneThe risk or severity of adverse effects can be increased when Iloperidone is combined with Clomipramine.
ImatinibThe metabolism of Clomipramine can be decreased when combined with Imatinib.
ImatinibThe serum concentration of Imatinib can be increased when it is combined with Clomipramine.
ImipramineThe risk or severity of adverse effects can be increased when Imipramine is combined with Clomipramine.
ImipramineThe serum concentration of Imipramine can be increased when it is combined with Clomipramine.
IndacaterolThe risk or severity of adverse effects can be increased when Clomipramine is combined with Indacaterol.
IndalpineThe risk or severity of adverse effects can be increased when Clomipramine is combined with Indalpine.
IndalpineIndalpine may increase the serotonergic activities of Clomipramine.
IndapamideClomipramine may increase the hyponatremic activities of Indapamide.
IndenololThe serum concentration of Indenolol can be increased when it is combined with Clomipramine.
IndinavirThe serum concentration of Clomipramine can be increased when it is combined with Indinavir.
IndomethacinThe serum concentration of Indomethacin can be increased when it is combined with Clomipramine.
Insulin AspartClomipramine may increase the hypoglycemic activities of Insulin Aspart.
Insulin DetemirClomipramine may increase the hypoglycemic activities of Insulin Detemir.
Insulin GlargineClomipramine may increase the hypoglycemic activities of Insulin Glargine.
Insulin GlulisineClomipramine may increase the hypoglycemic activities of Insulin Glulisine.
Insulin HumanClomipramine may increase the hypoglycemic activities of Insulin Human.
Insulin LisproClomipramine may increase the hypoglycemic activities of Insulin Lispro.
Ioflupane I-123Clomipramine may decrease effectiveness of Ioflupane I 123 as a diagnostic agent.
Ipratropium bromideThe metabolism of Ipratropium bromide can be decreased when combined with Clomipramine.
IproclozideIproclozide may increase the serotonergic activities of Clomipramine.
IproniazidIproniazid may increase the serotonergic activities of Clomipramine.
IrinotecanThe serum concentration of Irinotecan can be increased when it is combined with Clomipramine.
IsavuconazoniumThe metabolism of Clomipramine can be decreased when combined with Isavuconazonium.
IsocarboxazidIsocarboxazid may increase the serotonergic activities of Clomipramine.
IsocarboxazidThe risk or severity of adverse effects can be increased when Clomipramine is combined with Isocarboxazid.
IsoetarineThe risk or severity of adverse effects can be increased when Clomipramine is combined with Isoetarine.
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Clomipramine.
IsoflurophateThe serum concentration of Clomipramine can be increased when it is combined with Isoflurophate.
IsoniazidThe metabolism of Clomipramine can be decreased when combined with Isoniazid.
IsoprenalineThe risk or severity of adverse effects can be increased when Clomipramine is combined with Isoprenaline.
IsradipineThe metabolism of Clomipramine can be decreased when combined with Isradipine.
ItraconazoleThe metabolism of Clomipramine can be decreased when combined with Itraconazole.
IvacaftorThe serum concentration of Clomipramine can be increased when it is combined with Ivacaftor.
IvermectinThe serum concentration of Ivermectin can be increased when it is combined with Clomipramine.
IxazomibThe serum concentration of Clomipramine can be increased when it is combined with Ixazomib.
IxazomibThe metabolism of Ixazomib can be decreased when combined with Clomipramine.
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Clomipramine.
KetazolamThe risk or severity of adverse effects can be increased when Ketazolam is combined with Clomipramine.
KetazolamThe serum concentration of Ketazolam can be increased when it is combined with Clomipramine.
KetobemidoneKetobemidone may increase the serotonergic activities of Clomipramine.
KetobemidoneThe risk or severity of adverse effects can be increased when Clomipramine is combined with Ketobemidone.
KetoconazoleThe serum concentration of Ketoconazole can be increased when it is combined with Clomipramine.
KetoconazoleThe metabolism of Clomipramine can be decreased when combined with Ketoconazole.
L-TryptophanL-Tryptophan may increase the serotonergic activities of Clomipramine.
LabetalolThe serum concentration of Labetalol can be increased when it is combined with Clomipramine.
LamivudineThe serum concentration of Lamivudine can be increased when it is combined with Clomipramine.
LamotrigineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Clomipramine.
LamotrigineThe serum concentration of Lamotrigine can be increased when it is combined with Clomipramine.
LanreotideClomipramine may increase the hypoglycemic activities of Lanreotide.
LansoprazoleThe serum concentration of Lansoprazole can be increased when it is combined with Clomipramine.
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Clomipramine.
LenalidomideThe serum concentration of Lenalidomide can be increased when it is combined with Clomipramine.
LenvatinibClomipramine may increase the QTc-prolonging activities of Lenvatinib.
LepirudinThe serum concentration of Clomipramine can be increased when it is combined with Lepirudin.
LeuprolideClomipramine may increase the QTc-prolonging activities of Leuprolide.
LevetiracetamThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Clomipramine.
LevetiracetamThe serum concentration of Levetiracetam can be increased when it is combined with Clomipramine.
LevobunololThe serum concentration of Levobunolol can be increased when it is combined with Clomipramine.
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Clomipramine.
LevocabastineThe risk or severity of adverse effects can be increased when Levocabastine is combined with Clomipramine.
LevocetirizineThe risk or severity of adverse effects can be increased when Levocetirizine is combined with Clomipramine.
LevodopaThe risk or severity of adverse effects can be increased when Levodopa is combined with Clomipramine.
LevodopaThe metabolism of Levodopa can be decreased when combined with Clomipramine.
LevofloxacinClomipramine may increase the QTc-prolonging activities of Levofloxacin.
Levomethadyl AcetateLevomethadyl Acetate may increase the serotonergic activities of Clomipramine.
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Clomipramine is combined with Levomethadyl Acetate.
LevomilnacipranThe risk or severity of adverse effects can be increased when Clomipramine is combined with Levomilnacipran.
LevomilnacipranLevomilnacipran may increase the serotonergic activities of Clomipramine.
LevorphanolLevorphanol may increase the serotonergic activities of Clomipramine.
LevorphanolThe risk or severity of adverse effects can be increased when Clomipramine is combined with Levorphanol.
LevothyroxineThe therapeutic efficacy of Levothyroxine can be decreased when used in combination with Clomipramine.
LevothyroxineLevothyroxine may increase the arrhythmogenic activities of Clomipramine.
LidocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Clomipramine.
LidocaineThe metabolism of Lidocaine can be decreased when combined with Clomipramine.
LinagliptinThe serum concentration of Clomipramine can be increased when it is combined with Linagliptin.
LinezolidLinezolid may increase the serotonergic activities of Clomipramine.
LinezolidThe risk or severity of adverse effects can be increased when Clomipramine is combined with Linezolid.
LiothyronineThe therapeutic efficacy of Liothyronine can be decreased when used in combination with Clomipramine.
LiothyronineLiothyronine may increase the arrhythmogenic activities of Clomipramine.
LiotrixThe therapeutic efficacy of Liotrix can be decreased when used in combination with Clomipramine.
LiotrixLiotrix may increase the arrhythmogenic activities of Clomipramine.
LiraglutideClomipramine may increase the hypoglycemic activities of Liraglutide.
LisdexamfetamineClomipramine may increase the stimulatory activities of Lisdexamfetamine.
LisinoprilThe serum concentration of Clomipramine can be increased when it is combined with Lisinopril.
LisurideThe metabolism of Lisuride can be decreased when combined with Clomipramine.
LithiumThe risk or severity of adverse effects can be increased when Lithium is combined with Clomipramine.
LofentanilLofentanil may increase the serotonergic activities of Clomipramine.
LofentanilThe risk or severity of adverse effects can be increased when Clomipramine is combined with Lofentanil.
LofexidineThe therapeutic efficacy of Lofexidine can be decreased when used in combination with Clomipramine.
LomustineThe metabolism of Lomustine can be decreased when combined with Clomipramine.
LoperamideThe serum concentration of Loperamide can be increased when it is combined with Clomipramine.
LopinavirThe serum concentration of Clomipramine can be increased when it is combined with Lopinavir.
LopinavirClomipramine may increase the QTc-prolonging activities of Lopinavir.
LoratadineThe risk or severity of adverse effects can be increased when Loratadine is combined with Clomipramine.
LoratadineThe metabolism of Loratadine can be decreased when combined with Clomipramine.
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Clomipramine.
LorcaserinThe metabolism of Lorcaserin can be decreased when combined with Clomipramine.
LosartanThe serum concentration of Losartan can be increased when it is combined with Clomipramine.
LovastatinThe metabolism of Clomipramine can be decreased when combined with Lovastatin.
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Clomipramine.
Lu AA21004The risk or severity of adverse effects can be increased when Lu AA21004 is combined with Clomipramine.
LuliconazoleThe serum concentration of Clomipramine can be increased when it is combined with Luliconazole.
LumacaftorThe serum concentration of Clomipramine can be decreased when it is combined with Lumacaftor.
LumefantrineClomipramine may increase the QTc-prolonging activities of Lumefantrine.
LumefantrineThe metabolism of Clomipramine can be decreased when combined with Lumefantrine.
LurasidoneThe risk or severity of adverse effects can be increased when Lurasidone is combined with Clomipramine.
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Clomipramine.
Magnesium SulfateThe risk or severity of adverse effects can be increased when Clomipramine is combined with Magnesium Sulfate.
MannitolThe serum concentration of Mannitol can be increased when it is combined with Clomipramine.
MaprotilineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Clomipramine.
MaprotilineThe metabolism of Maprotiline can be decreased when combined with Clomipramine.
MebanazineMebanazine may increase the serotonergic activities of Clomipramine.
MecaserminClomipramine may increase the hypoglycemic activities of Mecasermin.
MeclizineThe risk or severity of adverse effects can be increased when Meclizine is combined with Clomipramine.
MedetomidineThe risk or severity of adverse effects can be increased when Medetomidine is combined with Clomipramine.
MelatoninThe risk or severity of adverse effects can be increased when Melatonin is combined with Clomipramine.
MelperoneThe risk or severity of adverse effects can be increased when Melperone is combined with Clomipramine.
MephentermineClomipramine may increase the stimulatory activities of Mephentermine.
MephenytoinThe metabolism of Mephenytoin can be decreased when combined with Clomipramine.
MepivacaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Clomipramine.
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Clomipramine.
MequitazineThe metabolism of Mequitazine can be decreased when combined with Clomipramine.
MesoridazineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Clomipramine.
MetaraminolClomipramine may increase the vasopressor activities of Metaraminol.
MetaxaloneThe risk or severity of adverse effects can be increased when Metaxalone is combined with Clomipramine.
MetforminClomipramine may increase the hypoglycemic activities of Metformin.
MethadoneMethadone may increase the serotonergic activities of Clomipramine.
MethadoneClomipramine may increase the QTc-prolonging activities of Methadone.
Methadyl AcetateMethadyl Acetate may increase the serotonergic activities of Clomipramine.
Methadyl AcetateThe risk or severity of adverse effects can be increased when Clomipramine is combined with Methadyl Acetate.
MethamphetamineClomipramine may increase the stimulatory activities of Methamphetamine.
MethapyrileneThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Clomipramine.
MethaqualoneThe risk or severity of adverse effects can be increased when Methaqualone is combined with Clomipramine.
MethocarbamolThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Clomipramine.
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Clomipramine.
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Clomipramine.
MethotrimeprazineThe risk or severity of adverse effects can be increased when Methotrimeprazine is combined with Clomipramine.
MethoxamineClomipramine may increase the vasopressor activities of Methoxamine.
MethoxyfluraneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Clomipramine.
MethoxyfluraneThe metabolism of Methoxyflurane can be decreased when combined with Clomipramine.
MethsuximideThe risk or severity of adverse effects can be increased when Methsuximide is combined with Clomipramine.
MethyclothiazideClomipramine may increase the hyponatremic activities of Methyclothiazide.
Methylene blueClomipramine may increase the serotonergic activities of Methylene blue.
MethylphenidateThe risk or severity of adverse effects can be increased when Methylphenidate is combined with Clomipramine.
MethylphenidateThe metabolism of Methylphenidate can be decreased when combined with Clomipramine.
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Clomipramine.
MethylprednisoloneThe serum concentration of Methylprednisolone can be increased when it is combined with Clomipramine.
MethyprylonThe metabolism of Methyprylon can be decreased when combined with Clomipramine.
MetipranololThe serum concentration of Metipranolol can be increased when it is combined with Clomipramine.
MetoclopramideThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Clomipramine.
MetolazoneClomipramine may increase the hyponatremic activities of Metolazone.
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Clomipramine.
MetoprololThe metabolism of Clomipramine can be decreased when combined with Metoprolol.
MetyrosineThe risk or severity of adverse effects can be increased when Metyrosine is combined with Clomipramine.
MetyrosineClomipramine may increase the sedative activities of Metyrosine.
MexiletineThe metabolism of Clomipramine can be decreased when combined with Mexiletine.
MianserinThe metabolism of Mianserin can be decreased when combined with Clomipramine.
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Clomipramine.
MidazolamThe serum concentration of Midazolam can be increased when it is combined with Clomipramine.
MidodrineClomipramine may increase the vasopressor activities of Midodrine.
MifepristoneClomipramine may increase the hypoglycemic activities of Mifepristone.
MifepristoneThe metabolism of Clomipramine can be decreased when combined with Mifepristone.
MiglitolClomipramine may increase the hypoglycemic activities of Miglitol.
MilnacipranThe risk or severity of adverse effects can be increased when Clomipramine is combined with Milnacipran.
MilnacipranMilnacipran may increase the serotonergic activities of Clomipramine.
MinaprineMinaprine may increase the serotonergic activities of Clomipramine.
MinaprineThe metabolism of Minaprine can be decreased when combined with Clomipramine.
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Clomipramine.
MirabegronThe serum concentration of Mirabegron can be increased when it is combined with Clomipramine.
MirabegronThe metabolism of Clomipramine can be decreased when combined with Mirabegron.
MirtazapineClomipramine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
MirtazapineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Clomipramine.
MitotaneThe serum concentration of Clomipramine can be decreased when it is combined with Mitotane.
MitoxantroneThe serum concentration of Mitoxantrone can be increased when it is combined with Clomipramine.
MoclobemideMoclobemide may increase the serotonergic activities of Clomipramine.
MoclobemideThe metabolism of Moclobemide can be decreased when combined with Clomipramine.
ModafinilThe serum concentration of Clomipramine can be decreased when it is combined with Modafinil.
MoexiprilThe serum concentration of Clomipramine can be increased when it is combined with Moexipril.
MolindoneThe risk or severity of adverse effects can be increased when Molindone is combined with Clomipramine.
MoricizineThe risk or severity of adverse effects can be increased when Moricizine is combined with Clomipramine.
MorphineMorphine may increase the serotonergic activities of Clomipramine.
MorphineThe serum concentration of Morphine can be increased when it is combined with Clomipramine.
MoxifloxacinClomipramine may increase the QTc-prolonging activities of Moxifloxacin.
MoxonidineThe therapeutic efficacy of Moxonidine can be decreased when used in combination with Clomipramine.
Mycophenolate mofetilThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Clomipramine.
N-(3-Propylcarbamoyloxirane-2-Carbonyl)-Isoleucyl-ProlineThe serum concentration of Clomipramine can be increased when it is combined with N-(3-Propylcarbamoyloxirane-2-Carbonyl)-Isoleucyl-Proline.
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Clomipramine.
NabiloneThe risk or severity of adverse effects can be increased when Clomipramine is combined with Nabilone.
NadololThe serum concentration of Nadolol can be increased when it is combined with Clomipramine.
NafcillinThe serum concentration of Clomipramine can be decreased when it is combined with Nafcillin.
NalbuphineNalbuphine may increase the serotonergic activities of Clomipramine.
NalbuphineThe risk or severity of adverse effects can be increased when Clomipramine is combined with Nalbuphine.
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Clomipramine.
NaloxoneThe serum concentration of Naloxone can be increased when it is combined with Clomipramine.
NaphazolineThe therapeutic efficacy of Naphazoline can be decreased when used in combination with Clomipramine.
NaratriptanThe risk or severity of adverse effects can be increased when Naratriptan is combined with Clomipramine.
NateglinideClomipramine may increase the hypoglycemic activities of Nateglinide.
NCX 4016The serum concentration of Clomipramine can be increased when it is combined with NCX 4016.
NebivololThe serum concentration of Nebivolol can be increased when it is combined with Clomipramine.
NefazodoneThe metabolism of Clomipramine can be decreased when combined with Nefazodone.
NelfinavirThe serum concentration of Clomipramine can be increased when it is combined with Nelfinavir.
NetupitantThe serum concentration of Clomipramine can be increased when it is combined with Netupitant.
NetupitantThe metabolism of Netupitant can be decreased when combined with Clomipramine.
NevirapineThe metabolism of Clomipramine can be decreased when combined with Nevirapine.
NialamideNialamide may increase the serotonergic activities of Clomipramine.
NicardipineThe serum concentration of Nicardipine can be increased when it is combined with Clomipramine.
NicardipineThe metabolism of Clomipramine can be decreased when combined with Nicardipine.
NicergolineThe metabolism of Nicergoline can be decreased when combined with Clomipramine.
NicorandilClomipramine may increase the hypotensive activities of Nicorandil.
NicotineThe metabolism of Nicotine can be decreased when combined with Clomipramine.
NifedipineThe serum concentration of Nifedipine can be increased when it is combined with Clomipramine.
NilotinibThe metabolism of Clomipramine can be decreased when combined with Nilotinib.
NilotinibThe serum concentration of Nilotinib can be increased when it is combined with Clomipramine.
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Clomipramine.
NitrazepamThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Clomipramine.
NitrofuralThe metabolism of Nitrofural can be decreased when combined with Clomipramine.
Nitrous oxideThe risk or severity of adverse effects can be increased when Nitrous oxide is combined with Clomipramine.
NizatidineThe serum concentration of Nizatidine can be increased when it is combined with Clomipramine.
NorepinephrineThe therapeutic efficacy of Norepinephrine can be decreased when used in combination with Clomipramine.
NormethadoneNormethadone may increase the serotonergic activities of Clomipramine.
NormethadoneThe risk or severity of adverse effects can be increased when Clomipramine is combined with Normethadone.
NortriptylineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Clomipramine.
NortriptylineThe metabolism of Nortriptyline can be decreased when combined with Clomipramine.
OctamoxinOctamoxin may increase the serotonergic activities of Clomipramine.
OctreotideClomipramine may increase the hypoglycemic activities of Octreotide.
OfloxacinClomipramine may increase the QTc-prolonging activities of Ofloxacin.
OlanzapineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Clomipramine.
OlaparibThe metabolism of Clomipramine can be decreased when combined with Olaparib.
OlodaterolThe risk or severity of adverse effects can be increased when Clomipramine is combined with Olodaterol.
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Clomipramine.
OmapatrilatThe serum concentration of Clomipramine can be increased when it is combined with Omapatrilat.
OmbitasvirThe serum concentration of Ombitasvir can be increased when it is combined with Clomipramine.
OmeprazoleThe metabolism of Clomipramine can be decreased when combined with Omeprazole.
OndansetronThe risk or severity of adverse effects can be increased when Ondansetron is combined with Clomipramine.
OpiumOpium may increase the serotonergic activities of Clomipramine.
OpiumThe risk or severity of adverse effects can be increased when Clomipramine is combined with Opium.
OrciprenalineThe risk or severity of adverse effects can be increased when Clomipramine is combined with Orciprenaline.
OrphenadrineClomipramine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
OrphenadrineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Clomipramine.
OsanetantThe risk or severity of adverse effects can be increased when Osanetant is combined with Clomipramine.
OsimertinibThe serum concentration of Clomipramine can be increased when it is combined with Osimertinib.
OtamixabanThe serum concentration of Clomipramine can be increased when it is combined with Otamixaban.
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Clomipramine.
OxprenololThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Clomipramine.
OxprenololThe serum concentration of Oxprenolol can be increased when it is combined with Clomipramine.
OxybuprocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Clomipramine.
OxycodoneOxycodone may increase the serotonergic activities of Clomipramine.
OxycodoneThe metabolism of Oxycodone can be decreased when combined with Clomipramine.
OxymetazolineThe therapeutic efficacy of Oxymetazoline can be decreased when used in combination with Clomipramine.
OxymorphoneOxymorphone may increase the serotonergic activities of Clomipramine.
OxymorphoneThe metabolism of Oxymorphone can be decreased when combined with Clomipramine.
PaclitaxelThe serum concentration of Paclitaxel can be increased when it is combined with Clomipramine.
PalbociclibThe serum concentration of Clomipramine can be increased when it is combined with Palbociclib.
PaliperidoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Clomipramine.
PaliperidoneThe therapeutic efficacy of Paliperidone can be decreased when used in combination with Clomipramine.
PalonosetronPalonosetron may increase the serotonergic activities of Clomipramine.
PalonosetronThe metabolism of Palonosetron can be decreased when combined with Clomipramine.
PanobinostatClomipramine may increase the QTc-prolonging activities of Panobinostat.
PanobinostatThe metabolism of Clomipramine can be decreased when combined with Panobinostat.
PantoprazoleThe metabolism of Clomipramine can be decreased when combined with Pantoprazole.
ParaldehydeClomipramine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
ParaldehydeThe risk or severity of adverse effects can be increased when Paraldehyde is combined with Clomipramine.
PargylinePargyline may increase the serotonergic activities of Clomipramine.
ParoxetineThe risk or severity of adverse effects can be increased when Paroxetine is combined with Clomipramine.
PasireotideClomipramine may increase the hypoglycemic activities of Pasireotide.
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Clomipramine.
Peginterferon alfa-2bThe serum concentration of Clomipramine can be decreased when it is combined with Peginterferon alfa-2b.
PenbutololThe serum concentration of Penbutolol can be increased when it is combined with Clomipramine.
PentamidineClomipramine may increase the hypoglycemic activities of Pentamidine.
PentazocinePentazocine may increase the serotonergic activities of Clomipramine.
PentazocineThe risk or severity of adverse effects can be increased when Clomipramine is combined with Pentazocine.
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Clomipramine.
PerampanelThe risk or severity of adverse effects can be increased when Perampanel is combined with Clomipramine.
PerflutrenClomipramine may increase the QTc-prolonging activities of Perflutren.
PergolideThe therapeutic efficacy of Pergolide can be decreased when used in combination with Clomipramine.
PerhexilineThe metabolism of Perhexiline can be decreased when combined with Clomipramine.
PerindoprilThe serum concentration of Clomipramine can be increased when it is combined with Perindopril.
PerospironeThe risk or severity of adverse effects can be increased when Perospirone is combined with Clomipramine.
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Clomipramine.
PethidinePethidine may increase the serotonergic activities of Clomipramine.
PethidineThe metabolism of Pethidine can be decreased when combined with Clomipramine.
PhenacetinThe metabolism of Phenacetin can be decreased when combined with Clomipramine.
PhenelzinePhenelzine may increase the serotonergic activities of Clomipramine.
PhenelzineThe risk or severity of adverse effects can be increased when Clomipramine is combined with Phenelzine.
PhenforminThe metabolism of Phenformin can be decreased when combined with Clomipramine.
PhenindioneClomipramine may increase the anticoagulant activities of Phenindione.
PheniprazinePheniprazine may increase the serotonergic activities of Clomipramine.
PhenobarbitalThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Clomipramine.
PhenobarbitalThe serum concentration of Phenobarbital can be increased when it is combined with Clomipramine.
PhenoxyethanolThe risk or severity of adverse effects can be increased when Phenoxyethanol is combined with Clomipramine.
PhenoxypropazinePhenoxypropazine may increase the serotonergic activities of Clomipramine.
PhenprocoumonClomipramine may increase the anticoagulant activities of Phenprocoumon.
PhentermineClomipramine may increase the stimulatory activities of Phentermine.
PhenylephrineClomipramine may increase the vasopressor activities of Phenylephrine.
PhenylpropanolamineThe therapeutic efficacy of Phenylpropanolamine can be decreased when used in combination with Clomipramine.
PhenytoinThe risk or severity of adverse effects can be increased when Phenytoin is combined with Clomipramine.
PhenytoinThe serum concentration of Phenytoin can be increased when it is combined with Clomipramine.
PhosphoramidonThe serum concentration of Clomipramine can be increased when it is combined with Phosphoramidon.
PimozideThe risk or severity of adverse effects can be increased when Clomipramine is combined with Pimozide.
PindololThe serum concentration of Pindolol can be increased when it is combined with Clomipramine.
PioglitazoneClomipramine may increase the hypoglycemic activities of Pioglitazone.
PipamperoneThe risk or severity of adverse effects can be increased when Pipamperone is combined with Clomipramine.
PiperazineThe metabolism of Piperazine can be decreased when combined with Clomipramine.
PipotiazineThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Clomipramine.
PirbuterolThe risk or severity of adverse effects can be increased when Clomipramine is combined with Pirbuterol.
PirlindolePirlindole may increase the serotonergic activities of Clomipramine.
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Clomipramine.
PivhydrazinePivhydrazine may increase the serotonergic activities of Clomipramine.
PizotifenThe risk or severity of adverse effects can be increased when Pizotifen is combined with Clomipramine.
PolythiazideClomipramine may increase the hyponatremic activities of Polythiazide.
PomalidomideThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Clomipramine.
PomalidomideThe serum concentration of Pomalidomide can be increased when it is combined with Clomipramine.
PonatinibThe serum concentration of Ponatinib can be increased when it is combined with Clomipramine.
PosaconazoleThe metabolism of Clomipramine can be decreased when combined with Posaconazole.
PractololThe serum concentration of Practolol can be increased when it is combined with Clomipramine.
PramipexoleClomipramine may increase the sedative activities of Pramipexole.
PramlintideClomipramine may increase the hypoglycemic activities of Pramlintide.
PramocaineThe risk or severity of adverse effects can be increased when Pramocaine is combined with Clomipramine.
PravastatinThe serum concentration of Pravastatin can be increased when it is combined with Clomipramine.
PrazepamThe risk or severity of adverse effects can be increased when Prazepam is combined with Clomipramine.
PrazosinThe serum concentration of Prazosin can be increased when it is combined with Clomipramine.
PrednisoloneThe serum concentration of Prednisolone can be increased when it is combined with Clomipramine.
PrednisoneThe serum concentration of Prednisone can be increased when it is combined with Clomipramine.
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Clomipramine.
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Clomipramine.
PrimaquineClomipramine may increase the QTc-prolonging activities of Primaquine.
PrimidoneThe risk or severity of adverse effects can be increased when Primidone is combined with Clomipramine.
PrinomastatThe serum concentration of Clomipramine can be increased when it is combined with Prinomastat.
ProcainamideThe metabolism of Procainamide can be decreased when combined with Clomipramine.
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Clomipramine.
ProcarbazineThe risk or severity of adverse effects can be increased when Procarbazine is combined with Clomipramine.
ProcaterolThe risk or severity of adverse effects can be increased when Clomipramine is combined with Procaterol.
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Clomipramine.
ProgesteroneThe serum concentration of Progesterone can be increased when it is combined with Clomipramine.
PromazineThe risk or severity of adverse effects can be increased when Promazine is combined with Clomipramine.
PromethazineThe risk or severity of adverse effects can be increased when Promethazine is combined with Clomipramine.
PromethazineThe metabolism of Promethazine can be decreased when combined with Clomipramine.
PropafenoneThe serum concentration of Clomipramine can be increased when it is combined with Propafenone.
PropafenoneClomipramine may increase the QTc-prolonging activities of Propafenone.
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Clomipramine.
PropericiazineThe risk or severity of adverse effects can be increased when Clomipramine is combined with Propericiazine.
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Clomipramine.
PropofolThe metabolism of Propofol can be decreased when combined with Clomipramine.
PropoxycaineThe risk or severity of adverse effects can be increased when Propoxycaine is combined with Clomipramine.
PropranololThe serum concentration of Propranolol can be increased when it is combined with Clomipramine.
ProtriptylineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Clomipramine.
ProtriptylineThe metabolism of Protriptyline can be decreased when combined with Clomipramine.
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Clomipramine.
PSD502The risk or severity of adverse effects can be increased when PSD502 is combined with Clomipramine.
PseudoephedrineThe therapeutic efficacy of Pseudoephedrine can be decreased when used in combination with Clomipramine.
QuazepamThe risk or severity of adverse effects can be increased when Quazepam is combined with Clomipramine.
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Clomipramine.
QuinaprilThe serum concentration of Clomipramine can be increased when it is combined with Quinapril.
QuinethazoneClomipramine may increase the hyponatremic activities of Quinethazone.
QuinidineThe serum concentration of Quinidine can be increased when it is combined with Clomipramine.
QuinidineThe metabolism of Clomipramine can be decreased when combined with Quinidine.
QuinineClomipramine may increase the hypoglycemic activities of Quinine.
QuinineThe metabolism of Clomipramine can be decreased when combined with Quinine.
RamelteonThe risk or severity of adverse effects can be increased when Ramelteon is combined with Clomipramine.
RamiprilThe serum concentration of Clomipramine can be increased when it is combined with Ramipril.
RanitidineThe serum concentration of Ranitidine can be increased when it is combined with Clomipramine.
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Clomipramine.
RanolazineThe metabolism of Clomipramine can be decreased when combined with Ranolazine.
RasagilineRasagiline may increase the serotonergic activities of Clomipramine.
RasagilineThe risk or severity of adverse effects can be increased when Clomipramine is combined with Rasagiline.
RemifentanilRemifentanil may increase the serotonergic activities of Clomipramine.
RemifentanilThe risk or severity of adverse effects can be increased when Clomipramine is combined with Remifentanil.
RemikirenThe serum concentration of Clomipramine can be increased when it is combined with Remikiren.
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Clomipramine.
RepaglinideClomipramine may increase the hypoglycemic activities of Repaglinide.
repinotanThe metabolism of repinotan can be decreased when combined with Clomipramine.
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Clomipramine.
RifabutinThe metabolism of Clomipramine can be increased when combined with Rifabutin.
RifampicinThe metabolism of Clomipramine can be increased when combined with Rifampicin.
RifampicinThe serum concentration of Rifampicin can be increased when it is combined with Clomipramine.
RifapentineThe metabolism of Clomipramine can be increased when combined with Rifapentine.
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Clomipramine.
RisperidoneThe metabolism of Risperidone can be decreased when combined with Clomipramine.
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Clomipramine.
RitodrineThe risk or severity of adverse effects can be increased when Clomipramine is combined with Ritodrine.
RitonavirThe serum concentration of Clomipramine can be increased when it is combined with Ritonavir.
RivaroxabanThe serum concentration of Clomipramine can be increased when it is combined with Rivaroxaban.
RizatriptanThe risk or severity of adverse effects can be increased when Rizatriptan is combined with Clomipramine.
RolapitantThe metabolism of Clomipramine can be decreased when combined with Rolapitant.
RomidepsinThe serum concentration of Romidepsin can be increased when it is combined with Clomipramine.
RomifidineThe risk or severity of adverse effects can be increased when Romifidine is combined with Clomipramine.
RopiniroleClomipramine may increase the sedative activities of Ropinirole.
RopiniroleThe metabolism of Clomipramine can be decreased when combined with Ropinirole.
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Clomipramine.
RopivacaineThe metabolism of Ropivacaine can be decreased when combined with Clomipramine.
RosiglitazoneClomipramine may increase the hypoglycemic activities of Rosiglitazone.
RotigotineClomipramine may increase the sedative activities of Rotigotine.
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Clomipramine.
S-EthylisothioureaThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Clomipramine.
SafrazineSafrazine may increase the serotonergic activities of Clomipramine.
SalbutamolThe risk or severity of adverse effects can be increased when Clomipramine is combined with Salbutamol.
Salicylic acidThe serum concentration of Salicylic acid can be increased when it is combined with Clomipramine.
SalmeterolThe risk or severity of adverse effects can be increased when Clomipramine is combined with Salmeterol.
SaquinavirThe serum concentration of Clomipramine can be increased when it is combined with Saquinavir.
SaquinavirClomipramine may increase the QTc-prolonging activities of Saquinavir.
SaxagliptinClomipramine may increase the hypoglycemic activities of Saxagliptin.
SaxagliptinThe serum concentration of Clomipramine can be increased when it is combined with Saxagliptin.
ScopolamineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Clomipramine.
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Clomipramine.
SelegilineSelegiline may increase the serotonergic activities of Clomipramine.
SelegilineThe risk or severity of adverse effects can be increased when Clomipramine is combined with Selegiline.
SelexipagThe serum concentration of Selexipag can be increased when it is combined with Clomipramine.
SertindoleThe risk or severity of adverse effects can be increased when Sertindole is combined with Clomipramine.
SertralineThe risk or severity of adverse effects can be increased when Clomipramine is combined with Sertraline.
SertralineThe metabolism of Clomipramine can be decreased when combined with Sertraline.
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Clomipramine.
SildenafilThe metabolism of Clomipramine can be decreased when combined with Sildenafil.
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Clomipramine.
SiltuximabThe serum concentration of Clomipramine can be decreased when it is combined with Siltuximab.
SimeprevirThe serum concentration of Clomipramine can be increased when it is combined with Simeprevir.
SimvastatinThe metabolism of Simvastatin can be decreased when combined with Clomipramine.
SitagliptinClomipramine may increase the hypoglycemic activities of Sitagliptin.
SitagliptinThe serum concentration of Clomipramine can be increased when it is combined with Sitagliptin.
Sodium oxybateThe risk or severity of adverse effects can be increased when Sodium oxybate is combined with Clomipramine.
SofosbuvirThe serum concentration of Sofosbuvir can be increased when it is combined with Clomipramine.
SorafenibThe serum concentration of Sorafenib can be increased when it is combined with Clomipramine.
SotalolThe serum concentration of Sotalol can be increased when it is combined with Clomipramine.
SparfloxacinThe serum concentration of Sparfloxacin can be increased when it is combined with Clomipramine.
SparteineThe metabolism of Sparteine can be decreased when combined with Clomipramine.
SphingosineThe serum concentration of Sphingosine can be increased when it is combined with Clomipramine.
SpiraprilThe serum concentration of Clomipramine can be increased when it is combined with Spirapril.
St. John's WortThe serum concentration of Clomipramine can be decreased when it is combined with St. John's Wort.
StiripentolThe risk or severity of adverse effects can be increased when Stiripentol is combined with Clomipramine.
SufentanilSufentanil may increase the serotonergic activities of Clomipramine.
SufentanilThe risk or severity of adverse effects can be increased when Clomipramine is combined with Sufentanil.
SulfadiazineClomipramine may increase the hypoglycemic activities of Sulfadiazine.
SulfamethoxazoleClomipramine may increase the hypoglycemic activities of Sulfamethoxazole.
SulfisoxazoleClomipramine may increase the hypoglycemic activities of Sulfisoxazole.
SulfisoxazoleThe metabolism of Clomipramine can be decreased when combined with Sulfisoxazole.
SulpirideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Clomipramine.
SumatriptanThe risk or severity of adverse effects can be increased when Sumatriptan is combined with Clomipramine.
SunitinibClomipramine may increase the hypoglycemic activities of Sunitinib.
SuvorexantThe risk or severity of adverse effects can be increased when Suvorexant is combined with Clomipramine.
TacrolimusThe metabolism of Tacrolimus can be decreased when combined with Clomipramine.
TamoxifenThe serum concentration of Tamoxifen can be increased when it is combined with Clomipramine.
TamsulosinThe metabolism of Tamsulosin can be decreased when combined with Clomipramine.
TapentadolTapentadol may increase the serotonergic activities of Clomipramine.
TapentadolThe metabolism of Tapentadol can be decreased when combined with Clomipramine.
TasimelteonThe risk or severity of adverse effects can be increased when Tasimelteon is combined with Clomipramine.
Taurocholic AcidThe serum concentration of Taurocholic Acid can be increased when it is combined with Clomipramine.
Technetium Tc-99m sestamibiThe serum concentration of Technetium Tc-99m sestamibi can be increased when it is combined with Clomipramine.
Tedizolid PhosphateTedizolid Phosphate may increase the serotonergic activities of Clomipramine.
Tedizolid PhosphateThe risk or severity of adverse effects can be increased when Clomipramine is combined with Tedizolid Phosphate.
TegaserodThe metabolism of Tegaserod can be decreased when combined with Clomipramine.
TelaprevirThe serum concentration of Clomipramine can be increased when it is combined with Telaprevir.
TelavancinClomipramine may increase the QTc-prolonging activities of Telavancin.
TelithromycinClomipramine may increase the QTc-prolonging activities of Telithromycin.
TelithromycinThe metabolism of Clomipramine can be decreased when combined with Telithromycin.
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Clomipramine.
TemocaprilThe serum concentration of Clomipramine can be increased when it is combined with Temocapril.
TemsirolimusThe serum concentration of Temsirolimus can be increased when it is combined with Clomipramine.
TenofovirThe metabolism of Clomipramine can be decreased when combined with Tenofovir.
TerbinafineThe metabolism of Clomipramine can be decreased when combined with Terbinafine.
TerbutalineThe risk or severity of adverse effects can be increased when Clomipramine is combined with Terbutaline.
TerfenadineThe metabolism of Terfenadine can be decreased when combined with Clomipramine.
TeriflunomideThe serum concentration of Clomipramine can be decreased when it is combined with Teriflunomide.
TesmilifeneThe metabolism of Tesmilifene can be decreased when combined with Clomipramine.
TetrabenazineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Clomipramine.
TetrabenazineThe metabolism of Tetrabenazine can be decreased when combined with Clomipramine.
TetracaineThe risk or severity of adverse effects can be increased when Tetracaine is combined with Clomipramine.
TetrodotoxinThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Clomipramine.
ThalidomideClomipramine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
ThalidomideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Clomipramine.
TheophyllineThe metabolism of Clomipramine can be decreased when combined with Theophylline.
ThiamylalThe risk or severity of adverse effects can be increased when Thiamylal is combined with Clomipramine.
ThiethylperazineThe risk or severity of adverse effects can be increased when Thiethylperazine is combined with Clomipramine.
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Clomipramine.
ThioproperazineThe risk or severity of adverse effects can be increased when Clomipramine is combined with Thioproperazine.
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Clomipramine.
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Clomipramine.
ThiorphanThe serum concentration of Clomipramine can be increased when it is combined with Thiorphan.
ThiothixeneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Clomipramine.
Thyroid, porcineThe therapeutic efficacy of Thyroid, porcine can be decreased when used in combination with Clomipramine.
Thyroid, porcineThyroid, porcine may increase the arrhythmogenic activities of Clomipramine.
TiagabineThe risk or severity of adverse effects can be increased when Tiagabine is combined with Clomipramine.
TicagrelorThe serum concentration of Ticagrelor can be increased when it is combined with Clomipramine.
TiclopidineThe metabolism of Clomipramine can be decreased when combined with Ticlopidine.
TiletamineThe risk or severity of adverse effects can be increased when Tiletamine is combined with Clomipramine.
TimololThe serum concentration of Timolol can be increased when it is combined with Clomipramine.
TiotropiumThe metabolism of Tiotropium can be decreased when combined with Clomipramine.
TipranavirThe serum concentration of Clomipramine can be increased when it is combined with Tipranavir.
TipranavirThe metabolism of Tipranavir can be decreased when combined with Clomipramine.
TizanidineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Clomipramine.
TizanidineThe therapeutic efficacy of Tizanidine can be decreased when used in combination with Clomipramine.
TocilizumabThe serum concentration of Clomipramine can be decreased when it is combined with Tocilizumab.
TolazamideClomipramine may increase the hypoglycemic activities of Tolazamide.
TolbutamideClomipramine may increase the hypoglycemic activities of Tolbutamide.
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Clomipramine.
ToloxatoneToloxatone may increase the serotonergic activities of Clomipramine.
TolterodineThe metabolism of Tolterodine can be decreased when combined with Clomipramine.
TolvaptanThe serum concentration of Tolvaptan can be increased when it is combined with Clomipramine.
TopiramateThe risk or severity of adverse effects can be increased when Topiramate is combined with Clomipramine.
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Clomipramine.
ToremifeneThe serum concentration of Toremifene can be increased when it is combined with Clomipramine.
TrabectedinThe metabolism of Trabectedin can be decreased when combined with Clomipramine.
TramadolThe therapeutic efficacy of Tramadol can be decreased when used in combination with Clomipramine.
TramadolTramadol may increase the serotonergic activities of Clomipramine.
TrandolaprilThe serum concentration of Clomipramine can be increased when it is combined with Trandolapril.
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the serotonergic activities of Clomipramine.
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Clomipramine is combined with Trans-2-Phenylcyclopropylamine.
TranylcypromineTranylcypromine may increase the serotonergic activities of Clomipramine.
TranylcypromineThe risk or severity of adverse effects can be increased when Clomipramine is combined with Tranylcypromine.
Trastuzumab emtansineThe serum concentration of Trastuzumab emtansine can be increased when it is combined with Clomipramine.
TrazodoneThe risk or severity of adverse effects can be increased when Trazodone is combined with Clomipramine.
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Clomipramine.
TrichlormethiazideClomipramine may increase the hyponatremic activities of Trichlormethiazide.
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Clomipramine.
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Clomipramine.
TrimipramineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Clomipramine.
TrimipramineThe metabolism of Trimipramine can be decreased when combined with Clomipramine.
TriprolidineThe risk or severity of adverse effects can be increased when Triprolidine is combined with Clomipramine.
UbenimexThe serum concentration of Clomipramine can be increased when it is combined with Ubenimex.
UlipristalThe serum concentration of Ulipristal can be increased when it is combined with Clomipramine.
UmeclidiniumThe serum concentration of Umeclidinium can be increased when it is combined with Clomipramine.
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Clomipramine.
VandetanibClomipramine may increase the QTc-prolonging activities of Vandetanib.
VecuroniumThe serum concentration of Vecuronium can be increased when it is combined with Clomipramine.
VemurafenibThe serum concentration of Clomipramine can be increased when it is combined with Vemurafenib.
VemurafenibClomipramine may increase the QTc-prolonging activities of Vemurafenib.
VenlafaxineThe metabolism of Clomipramine can be decreased when combined with Venlafaxine.
VenlafaxineThe serum concentration of Venlafaxine can be increased when it is combined with Clomipramine.
VerapamilThe metabolism of Clomipramine can be decreased when combined with Verapamil.
VerapamilThe serum concentration of Verapamil can be increased when it is combined with Clomipramine.
VigabatrinThe risk or severity of adverse effects can be increased when Vigabatrin is combined with Clomipramine.
VilanterolThe risk or severity of adverse effects can be increased when Clomipramine is combined with Vilanterol.
VilazodoneThe risk or severity of adverse effects can be increased when Clomipramine is combined with Vilazodone.
VilazodoneVilazodone may increase the serotonergic activities of Clomipramine.
VildagliptinThe serum concentration of Clomipramine can be increased when it is combined with Vildagliptin.
VinblastineThe serum concentration of Vinblastine can be increased when it is combined with Clomipramine.
VincristineThe serum concentration of Vincristine can be increased when it is combined with Clomipramine.
VinorelbineThe metabolism of Vinorelbine can be decreased when combined with Clomipramine.
VismodegibThe serum concentration of Vismodegib can be increased when it is combined with Clomipramine.
VoriconazoleThe metabolism of Clomipramine can be decreased when combined with Voriconazole.
VortioxetineThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Clomipramine.
WarfarinClomipramine may increase the anticoagulant activities of Warfarin.
XimelagatranThe serum concentration of Clomipramine can be increased when it is combined with Ximelagatran.
XylazineThe risk or severity of adverse effects can be increased when Xylazine is combined with Clomipramine.
XylometazolineThe therapeutic efficacy of Xylometazoline can be decreased when used in combination with Clomipramine.
YohimbineThe serum concentration of Yohimbine can be increased when it is combined with Clomipramine.
ZalcitabineThe metabolism of Zalcitabine can be decreased when combined with Clomipramine.
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Clomipramine.
ZiconotideThe risk or severity of adverse effects can be increased when Ziconotide is combined with Clomipramine.
ZidovudineThe serum concentration of Zidovudine can be increased when it is combined with Clomipramine.
ZimelidineThe risk or severity of adverse effects can be increased when Clomipramine is combined with Zimelidine.
ZimelidineZimelidine may increase the serotonergic activities of Clomipramine.
ZiprasidoneThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Clomipramine.
ZolazepamThe risk or severity of adverse effects can be increased when Zolazepam is combined with Clomipramine.
ZolmitriptanThe risk or severity of adverse effects can be increased when Zolmitriptan is combined with Clomipramine.
ZolpidemThe risk or severity of adverse effects can be increased when Zolpidem is combined with Clomipramine.
ZolpidemThe metabolism of Zolpidem can be decreased when combined with Clomipramine.
ZonisamideThe risk or severity of adverse effects can be increased when Zonisamide is combined with Clomipramine.
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Clomipramine.
ZotepineThe risk or severity of adverse effects can be increased when Zotepine is combined with Clomipramine.
ZuclopenthixolThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Clomipramine.
Food Interactions
  • Avoid alcohol.
  • Grapefruit and grapefruit juice should be avoided throughout treatment, grapefruit can modify serum levels of clomipramine and its metabolite desmethyl-clomipramine.
  • Take with food to reduce irritation.

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Serotonin:sodium symporter activity
Specific Function:
Serotonin transporter whose primary function in the central nervous system involves the regulation of serotonergic signaling via transport of serotonin molecules from the synaptic cleft back into the pre-synaptic terminal for re-utilization. Plays a key role in mediating regulation of the availability of serotonin to other receptors of serotonergic systems. Terminates the action of serotonin an...
Gene Name:
SLC6A4
Uniprot ID:
P31645
Molecular Weight:
70324.165 Da
References
  1. Alvarez JC, Gluck N, Arnulf I, Quintin P, Leboyer M, Pecquery R, Launay JM, Perez-Diaz F, Spreux-Varoquaux O: Decreased platelet serotonin transporter sites and increased platelet inositol triphosphate levels in patients with unipolar depression: effects of clomipramine and fluoxetine. Clin Pharmacol Ther. 1999 Dec;66(6):617-24. [PubMed:10613618 ]
  2. Borkowska A, Pilaczynska E, Araszkiewicz A, Rybakowski J: [The effect of sertraline on cognitive functions in patients with obsessive-compulsive disorder]. Psychiatr Pol. 2002 Nov-Dec;36(6 Suppl):289-95. [PubMed:12647451 ]
  3. Suhara T, Takano A, Sudo Y, Ichimiya T, Inoue M, Yasuno F, Ikoma Y, Okubo Y: High levels of serotonin transporter occupancy with low-dose clomipramine in comparative occupancy study with fluvoxamine using positron emission tomography. Arch Gen Psychiatry. 2003 Apr;60(4):386-91. [PubMed:12695316 ]
  4. Larsen AK, Brennum LT, Egebjerg J, Sanchez C, Halldin C, Andersen PH: Selectivity of (3)H-MADAM binding to 5-hydroxytryptamine transporters in vitro and in vivo in mice; correlation with behavioural effects. Br J Pharmacol. 2004 Mar;141(6):1015-23. Epub 2004 Mar 1. [PubMed:14993096 ]
  5. Malizia AL, Melichar JM, Brown DJ, Gunn RN, Reynolds A, Jones T, Nutt DJ: Demonstration of clomipramine and venlafaxine occupation at serotonin reuptake sites in man in vivo. J Psychopharmacol. 1997;11(3):279-81. [PubMed:9305421 ]
  6. Tatsumi M, Groshan K, Blakely RD, Richelson E: Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol. 1997 Dec 11;340(2-3):249-58. [PubMed:9537821 ]
  7. Gillman PK: Tricyclic antidepressant pharmacology and therapeutic drug interactions updated. Br J Pharmacol. 2007 Jul;151(6):737-48. Epub 2007 Apr 30. [PubMed:17471183 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Virus receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including mescaline, psilocybin, 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI) and lysergic acid diethylamide (LSD). Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates...
Gene Name:
HTR2A
Uniprot ID:
P28223
Molecular Weight:
52602.58 Da
References
  1. Hentall ID, Kurle PJ, White TR: Correlations between serotonin level and single-cell firing in the rat's nucleus raphe magnus. Neuroscience. 2000;95(4):1081-8. [PubMed:10682715 ]
  2. Contreras CM, Marvan ML, Munoz-Mendez A, Ramirez-Morales A: Cortical and septal responses to dorsal raphe nucleus stimulation in the rat: long-term clomipramine actions. Bol Estud Med Biol. 1992 Jan-Dec;40(1-4):3-7. [PubMed:1296670 ]
  3. Sugimoto Y, Inoue K, Yamada J: The tricyclic antidepressant clomipramine increases plasma glucose levels of mice. J Pharmacol Sci. 2003 Sep;93(1):74-9. [PubMed:14501155 ]
  4. Trifunovic RD, Brodie MS: The effects of clomipramine on the excitatory action of ethanol on dopaminergic neurons of the ventral tegmental area in vitro. J Pharmacol Exp Ther. 1996 Jan;276(1):34-40. [PubMed:8558452 ]
  5. Sargent PA, Quested DJ, Cowen PJ: Clomipramine enhances the cortisol response to 5-HTP: implications for the therapeutic role of 5-HT2 receptors. Psychopharmacology (Berl). 1998 Nov;140(1):120-2. [PubMed:9862411 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Serotonin receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various ergot alkaloid derivatives and psychoactive substances. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors. Beta-arrestin family members inhibit signaling via G proteins ...
Gene Name:
HTR2B
Uniprot ID:
P41595
Molecular Weight:
54297.41 Da
References
  1. Sargent PA, Quested DJ, Cowen PJ: Clomipramine enhances the cortisol response to 5-HTP: implications for the therapeutic role of 5-HT2 receptors. Psychopharmacology (Berl). 1998 Nov;140(1):120-2. [PubMed:9862411 ]
  2. Sugimoto Y, Inoue K, Yamada J: The tricyclic antidepressant clomipramine increases plasma glucose levels of mice. J Pharmacol Sci. 2003 Sep;93(1):74-9. [PubMed:14501155 ]
  3. Contreras CM, Marvan ML, Munoz-Mendez A, Ramirez-Morales A: Cortical and septal responses to dorsal raphe nucleus stimulation in the rat: long-term clomipramine actions. Bol Estud Med Biol. 1992 Jan-Dec;40(1-4):3-7. [PubMed:1296670 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Serotonin receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including ergot alkaloid derivatives, 1-2,5,-dimethoxy-4-iodophenyl-2-aminopropane (DOI) and lysergic acid diethylamide (LSD). Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modul...
Gene Name:
HTR2C
Uniprot ID:
P28335
Molecular Weight:
51820.705 Da
References
  1. Sargent PA, Quested DJ, Cowen PJ: Clomipramine enhances the cortisol response to 5-HTP: implications for the therapeutic role of 5-HT2 receptors. Psychopharmacology (Berl). 1998 Nov;140(1):120-2. [PubMed:9862411 ]
  2. Sugimoto Y, Inoue K, Yamada J: The tricyclic antidepressant clomipramine increases plasma glucose levels of mice. J Pharmacol Sci. 2003 Sep;93(1):74-9. [PubMed:14501155 ]
  3. Contreras CM, Marvan ML, Munoz-Mendez A, Ramirez-Morales A: Cortical and septal responses to dorsal raphe nucleus stimulation in the rat: long-term clomipramine actions. Bol Estud Med Biol. 1992 Jan-Dec;40(1-4):3-7. [PubMed:1296670 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Norepinephrine:sodium symporter activity
Specific Function:
Amine transporter. Terminates the action of noradrenaline by its high affinity sodium-dependent reuptake into presynaptic terminals.
Gene Name:
SLC6A2
Uniprot ID:
P23975
Molecular Weight:
69331.42 Da
References
  1. Tatsumi M, Groshan K, Blakely RD, Richelson E: Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol. 1997 Dec 11;340(2-3):249-58. [PubMed:9537821 ]
  2. Jungkun G, Kuss HJ, Gsell W: Long-term effects of tricyclic antidepressants on norepinephrine kinetics in humans. J Neural Transm (Vienna). 2001;108(3):349-62. [PubMed:11341486 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
S-nitrosoglutathione binding
Specific Function:
Conjugation of reduced glutathione to a wide number of exogenous and endogenous hydrophobic electrophiles. Regulates negatively CDK5 activity via p25/p35 translocation to prevent neurodegeneration.
Gene Name:
GSTP1
Uniprot ID:
P09211
Molecular Weight:
23355.625 Da
References
  1. Baranczyk-Kuzma A, Sawicki J, Kuzma M, Jagiello J: [Tricyclic antidepressants as inhibitors of brain glutathione-S-transferase]. Pol Merkur Lekarski. 2001 Dec;11(66):472-5. [PubMed:11899840 ]
  2. Baranczyk-Kuzma A, Kuzma M, Gutowicz M, Kazmierczak B, Sawicki J: Glutathione S-transferase pi as a target for tricyclic antidepressants in human brain. Acta Biochim Pol. 2004;51(1):207-12. [PubMed:15094841 ]
  3. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  2. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and imipramine.
Gene Name:
CYP2C19
Uniprot ID:
P33261
Molecular Weight:
55930.545 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  2. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
  3. The P450 Program [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Most active in catalyzing 2-hydroxylation. Caffeine is metabolized primarily by cytochrome CYP1A2 in the liver through an initial N...
Gene Name:
CYP1A2
Uniprot ID:
P05177
Molecular Weight:
58293.76 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  2. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
  3. Source [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  2. The P450 Program [Link]

Carriers

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Toxic substance binding
Specific Function:
Serum albumin, the main protein of plasma, has a good binding capacity for water, Ca(2+), Na(+), K(+), fatty acids, hormones, bilirubin and drugs. Its main function is the regulation of the colloidal osmotic pressure of blood. Major zinc transporter in plasma, typically binds about 80% of all plasma zinc.
Gene Name:
ALB
Uniprot ID:
P02768
Molecular Weight:
69365.94 Da

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Mahar Doan KM, Humphreys JE, Webster LO, Wring SA, Shampine LJ, Serabjit-Singh CJ, Adkison KK, Polli JW: Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs. J Pharmacol Exp Ther. 2002 Dec;303(3):1029-37. [PubMed:12438524 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23